

Heart regeneration and repair after myocardial infarction – translational opportunities for novel therapeutics

Authors

Dr Thomas J Cahill^{1,2}, Professor Robin P. Choudhury^{2,3} & Professor Paul R. Riley¹

1. Department of Physiology, Anatomy & Genetics, University of Oxford
Sherrington Building
Oxford, OX1 3PT, U.K.

2. Department of Cardiovascular Medicine, University of Oxford
John Radcliffe Hospital
Oxford, OX3 9DU, U.K.

3. Oxford Acute Vascular Imaging Centre, University of Oxford
John Radcliffe Hospital, OX3 9DU, U.K.

Correspondence to

Professor Paul R. Riley
BHF Professor of Regenerative Medicine
Chair of Development and Cell Biology
Department of Physiology, Anatomy and Genetics
Sherrington Building
University of Oxford
South Parks Road
Oxford OX1 3PT
paul.riley@dpag.ox.ac.uk

Abstract

Current therapies for heart failure after myocardial infarction (MI) are limited and non-curative. Although regenerative approaches are receiving significant attention, clinical efforts involving transplantation of presumed stem and progenitor cells have largely failed. Recent studies of endogenous heart regeneration in model organisms such as the zebrafish and neonatal mouse are yielding novel mechanistic insights into the roles of cardiomyocyte proliferation, resident stem cell niches, neovascularisation, the immune system and the extracellular matrix. These findings have revealed novel pathways which might be therapeutically targeted to stimulate repair following MI, and provided lessons to guide future efforts toward heart regeneration through cellular reprogramming or cardiomyocyte transplantation.

Introduction

Heart failure (HF) is the consequence of cardiomyocyte death or dysfunction, most commonly caused by myocardial infarction (MI), hypertension, valve disease, infiltration, infection, chemotherapy or genetic cardiomyopathy.^{1,2} HF is a global disease challenge which affects an estimated 38 million people worldwide.³ Despite strides forward in the management of acute MI, HF remains common and the incidence may be increasing due to improved early survival with primary percutaneous coronary intervention.^{4,5} Healthcare costs associated with HF exceed \$30 billion annually in the USA alone and are projected to increase to almost \$70 billion by 2030.⁶ HF is a leading cause of hospitalization, adverse quality of life, and death, and a new diagnosis carries a worse prognosis than many cancers, with a survival rate of only 50% at 5 years.

Current therapies to prevent or delay progression of HF are limited. Conventional pharmacotherapy targets the maladaptive counter-regulatory mechanisms activated by left ventricular dysfunction (Box 1). This approach has yielded blockbuster agents over the last 20 years, including inhibitors of the renin-angiotensin system, the mineralocorticoid receptor, the sympathetic nervous system, and most recently, the natriuretic system (Figure 1).^{7,8} While these drugs reduce mortality, they fail to address the underlying loss of cardiomyocytes and vasculature and are intrinsically non-curative.

Regeneration of the heart by reconstitution of the cardiomyocyte substrate is a tantalising and potentially entirely disruptive approach to HF. Regeneration is seen widely across the animal kingdom, and can occur in humans, for example after liver injury. To date, clinical efforts towards cardiac regeneration have focused on cell-based therapies, including bone marrow-derived cells, mesenchymal stem cells and presumed cardiac progenitor cells (Table 1).^{9,10} While these studies have met safety endpoints, the effect on cardiac function has been small or negligible, which has prompted a search for novel approaches. Insights from endogenous heart regeneration in animal models such as the zebrafish and neonatal mouse are now yielding new understanding of innate mechanisms for complex organ repair. This includes the origins of new cardiomyocytes after injury, control of cardiomyocyte proliferation in

development and ageing, and the roles of developmental stem cell niches such as the epicardium.^{11,12}

In this Review, we will describe recent insights into the biology of heart regeneration gained in preclinical animal models and extrapolate these to a next generation of regenerative strategies for HF, including methods for augmentation of intrinsic repair, cell reprogramming and extrinsic cardiomyocyte replacement. Key steps needed to translate informed biology to novel therapeutic approaches and compounds, adapt existing clinical trial design and enhance interactions between scientists, clinicians and the pharmaceutical industry will be outlined.

Discovery of heart regeneration [H1]

Organ regeneration has long been recognized. In 1686, lizard tail regeneration was demonstrated to the Paris Academy of Sciences, and the first scientific reports of regeneration in *Hydra* were published by Abraham Trembley in the mid-18th century.

Regeneration of the injured heart was first recognised in amphibians and has now been described in a number of teleost fish and amphibians.¹³ The two-chambered heart of the zebrafish (*Danio rerio*) regenerates after damage caused by surgical resection of the cardiac apex, cryoinjury, cardiomyocyte ablation, or hypoxia-reoxygenation.¹⁴⁻¹⁷ Urodele amphibians, including the axolotl and newt, are also capable of complete heart regeneration. In both fish and amphibians, functional cardiomyocytes re-populate the injury site and transient scar is resolved over a variable period of 60-180 days depending on the injury mechanism.^{13,18,19}

Although previously thought to be restricted to fish and amphibians, Porrello *et al* reported heart regeneration in the neonatal mouse in 2011.^{20,21} After resection of the cardiac apex or surgical coronary artery ligation (to induce MI), regeneration occurred over ~ 21 days leaving only very minor residual scarring at the site of the ligature. Interestingly, this capacity for regeneration was restricted to a temporally privileged window of the first seven days after birth.

The revelation that regeneration can occur in the neonatal mouse has ignited the field and suggests that regenerative repair is not a unique program lost to mammals in evolution. Whilst regeneration in the postnatal setting may involve a repurposing of the ongoing growth response, it remains highly valuable as a means to identify trophic pathways to promote regeneration in the adult. Furthermore, several intriguing (albeit low level) studies support the concept of a temporally privileged period of regenerative repair in humans. These include a case report of a newborn infant with a large anterior myocardial infarction, which healed by regeneration with full functional recovery.²² Other case reports of functional regeneration after cardiac injury in infants, and a lack of scarring in children after cardiac surgery for congenital heart disease, support the concept of age-dependent regeneration in the human heart.^{23,24}

Mechanisms of heart regeneration [H1]

Regeneration is a finely orchestrated process which has parallels to organ formation during embryonic development, requiring control of cell division, differentiation, migration, integration and maturation.²⁵ Compared to development, regeneration from injury is complicated by the need to clear damaged or dead tissue, regulate inflammation, suppress overactive fibrosis, and reconstitute and integrate only a subsection of cardiomyocytes, extracellular matrix, blood vessel and lymphatic systems.²⁶ Studies of heart regeneration in key genetic model organisms, the zebrafish and the mouse, have heralded a number of insights into the underlying biological mechanisms of these processes.

Cardiomyocyte regeneration [H2]

Replacement of cardiomyocytes to restore structural and functional integrity is the *sine qua non* of heart regeneration. Identifying the source(s) of new cardiomyocytes and mechanisms controlling cardiomyocyte proliferation is critical to understanding the mechanisms of regeneration and to direct therapeutic strategies for humans.

Sources of cardiomyocytes in endogenous regeneration [H3]

In principle, new cardiomyocytes might be derived from the existing cardiomyocyte pool (either directly from mature cardiomyocytes or an intermediate cell type) or alternatively from a progenitor cell population, either resident in the heart or located remotely. Seminal studies in the zebrafish and mouse have addressed this question using genetic lineage tracing, employing the tamoxifen-inducible Cre-LoxP system to irreversibly label cardiomyocytes with a fluorescent reporter protein prior to injury.²⁷ Once the label is activated, all cardiomyocytes and their progeny express the fluorescent reporter, meaning that if new cardiomyocytes are labelled they have originated from the pre-existing pool. If not, it can be assumed that they have been derived from a non-cardiomyocyte progenitor. Two studies using this approach in the zebrafish have shown that almost all (~95%) new cardiomyocytes after injury are labelled, suggesting that cells in the pre-existing cardiomyocyte pool are capable of re-entering the cell cycle, dividing and migrating in order to effect regeneration.^{28,29} In the mouse, new cardiomyocytes formed during ageing and neonatal heart regeneration are also derived from

the pre-existing cardiomyocyte pool.^{21,30} In the infarcted non-regenerating adult mouse heart, some data support a minor contribution of a non-cardiomyocyte progenitor population (e.g. c-kit+ cells) to the development of new cardiomyocytes, but this remains controversial.^{31,32}

The concept of regeneration driven primarily by existing cardiomyocytes is a paradigm shift. Many of the first generation cell-therapy trials (Table 1) were inspired by the concept of bone-marrow derived progenitors, which had been reported to differentiate into cardiomyocytes, but this has been progressively discredited.³³⁻³⁵ The benefits of bone marrow mononuclear cells and mesenchymal stem cells seen in some clinical studies (Table 1) are increasingly ascribed to paracrine effects. Understanding whether human mature cardiomyocytes can proliferate, and the mechanisms by which this is controlled, is now a major research focus.

Cardiomyocyte proliferation in development, ageing and injury [H3]

Cardiomyocytes in mice and humans proliferate during heart development *in utero* and early postnatal life. After birth, most cardiomyocytes exit the cell cycle, a variable subset (~25% in humans) undergoing a further cycle of nuclear division without cell separation (cytokinesis), resulting in binucleation.³⁶ In humans, the adult heart has thus traditionally been considered incapable of further cell division, with growth being achieved by hypertrophy. In fact, increasing evidence suggests that cardiomyocytes do renew in the human heart, albeit at a low level. Relying on integration of carbon-14 into DNA during Cold War nuclear testing, Bergmann *et al* estimated that cardiomyocyte self-renewal occurs at a rate of 1% per year for adults aged 25 years, decreasing to 0.45% by 75 years.³⁷ Histological analysis of the human heart has identified phosphorylated histone H3, a marker of mitosis, in adults up to the age of approximately 20 years.³⁸ However, despite the apparent capacity for renewal, MI fails to activate effective proliferation. In the adult mouse, using co-registration of cardiomyocyte fluorescent labelling and [¹⁵N]thymidine labelling of DNA replication, Senyo *et al* reported that only 3% of infarct zone cardiomyocytes initiate DNA replication and nuclear division. Furthermore, whilst these cells became binucleated, almost none underwent cytokinesis to form a new daughter cell.³⁰

Control of cardiomyocyte proliferation [H3]

Environmental cues in the post-natal environment have been implicated in proliferative arrest of mammalian cardiomyocytes. After birth, the heart transitions from the relatively hypoxic intrauterine environment to normoxia, which is associated with a shift from glycolysis to oxidative phosphorylation, increased mitochondrial content and activity, production of reactive oxygen species and cardiomyocyte cell cycle arrest.³⁹ Scavenging of reactive oxygen species prolongs the neonatal regenerative window, whereas hyperoxia shortens it. During regeneration, re-activation of cell cycle activity is associated with hypoxic activation of Hif-1 α .⁴⁰ Other factors have been implicated in the loss of proliferative capacity postnatally, including upregulation of p38 MAPK and Meis1.^{41 42} Meis1, a member of the three amino acid loop extension transcription factor family, promotes cell cycle arrest via activation of the cyclin-dependent kinase inhibitors p15, p16 and p21. Inhibition of Meis1 extends the regenerative window in neonates and is capable of reactivating the cell cycle in adults.

Many of the emerging ligands and signalling pathways which govern cardiomyocyte proliferation in regeneration are familiar from developmental biology (Figure 2). Neuregulin1 (NRG1), an agonist for the ErbB2 and ErbB4 receptor tyrosine kinases of the epidermal growth factor receptor family, is a key mitogen during heart development.^{43,44} It is reactivated in perivascular cells during zebrafish heart regeneration and overexpression enhances cardiomyocyte proliferation even in the uninjured heart.⁴⁵ The transcription factor Hand2 is critical to cardiomyocyte development from the second heart field, with zebrafish mutants having a reduction in cardiomyocytes and mice showing abnormalities in the right ventricle and outflow tract region.^{46,47} Hand2 is upregulated in the injured zebrafish ventricle, and overexpression is sufficient to drive cardiomyocyte proliferation.⁴⁸ Similarly, Gata4, a zinc finger transcription factor known to regulate cardiomyocyte differentiation, migration, hypertrophy and survival, is required for neonatal mouse heart regeneration, acting via FGF16 to stimulate proliferation.⁴⁹ The Hippo pathway, comprising series of proteins which regulate the transcription factor YAP and its co-activator TAZ, is an evolutionarily conserved regulator of cell proliferation, growth, viability and organ size.⁵⁰ Forced expression of YAP in development leads to hyperproliferation and cardiac enlargement, and in mouse

regeneration, YAP promotes proliferation acting via insulin-like growth factor and Wnt signalling pathways.^{51,52} Finally, as in development, regeneration requires chromatin remodelling by Brg1, which controls proliferation through pro-proliferative Bmp10 and inhibition of p57^{kip2}.⁵³ Inhibition of Brg, or other SWI/SNF components such as baf60c and baf180, leads to blunted proliferation and failed regeneration.⁵⁴

Despite these insights, whether a mature mammalian cardiomyocyte can re-enter cell cycle and progress through to cytokinesis is unclear. In the zebrafish, cardiomyocytes are mononuclear and relatively “primitive”, and this appears to be a critical factor determining their ability to divide. Proliferation of the mononuclear cardiomyocyte population can be induced by NRG1 treatment after MI in mice, and based on nuclearity, the adult human heart might be more ‘regenerative’ than the mouse since it contains a higher proportion of mononuclear cardiomyocytes.⁵⁵ In addition, distinct subsets of cardiomyocytes may have differing abilities to proliferate: in zebrafish, the outermost ‘cortical’ zone proliferates early and rapidly in regeneration.⁵⁶ Cardiomyocyte proliferation requires cellular ‘de-differentiation’, defined by increased intercellular separation and loss of sarcomeric and Z-disc structure.²⁸ Dedifferentiation has been observed in the mammalian heart, and may be triggered by oncostatin M, a macrophage-derived cytokine related to IL6, but is poorly characterised at a molecular level.⁵⁷

Research priorities in the mammalian heart include identifying and tracking the key cardiomyocyte sub-population(s) capable of division in the adult, based on ploidy or other discriminating features. Characterising the markers and transcriptional pathways of cardiomyocytes undergoing dedifferentiation, replication, migration and maturation would be valuable and is achievable with single cell sequencing approaches.⁵⁸ The precise mechanisms which direct cardiomyocytes to undergo cell division as opposed to polyploidization (which seems to suppress further cell cycle-entry) also remain poorly understood.⁵⁹ In parallel, understanding the hierarchy, relative importance and overlap of extrinsic cues would help prioritise therapeutic targets. For example, alongside the soluble ligands discussed above, the autonomic nervous system is emerging as a regulator of

cardiomyocyte proliferation and may be potentially ripe for adjunctive targeting.^{60,61}

Neovascularisation: the role of the epicardium [H2]

Whilst PPCI is effective at restoring coronary blood flow in the major epicardial vessels following MI, failure to perfuse the microcirculation (microvascular occlusion, MVO) is common and is associated with poor wound healing, ventricular remodelling, heart failure and reduced overall survival.⁶² MVO is multifactorial and occurs due to endothelial cell death, inflammation, and physical plugging by thrombotic or plaque debris. Restoration of effective myocardial perfusion by regeneration or repair of the coronary microcirculation, comprising vascular endothelium, smooth muscle, fibroblast and pericytes, will be essential to achieve heart regeneration.

Coronary formation during development [H3]

Coronary formation during development is a blueprint for formation of new vessels. Coronary endothelial cells arise primarily from the sinus venosus, with an additional contribution from the inner lining of the heart, the endocardium, which generates coronary endothelium for the interventricular septum.⁶³⁻⁶⁵ The program of coronary vascular formation is directed by the epicardium, also known as the visceral pericardium, which acts as both a source of trophic factors and progenitor cells.⁶⁶ Formed at embryonic day 9.75 in the mouse (human Carnegie stage 11), the epicardium is an epithelial sheet which envelops the growing heart.⁶⁷

Epicardial-derived cells (EPDCs) invade the underlying myocardium and undergo epithelial-to-mesenchymal transition (EMT), giving rise to pericytes, smooth muscle and adventitial and interstitial fibroblasts.^{63,68} ⁶⁹ The epicardium also begins a signalling *pas de deux* with the myocardium, secreting growth factors supporting vasculogenesis and mitogens which support cardiomyocyte proliferation.⁶⁶ Physical or genetic ablation (through deletion of epicardial genes such as *Wt1*) leads to defects in coronary vessel formation and impaired cardiomyocyte proliferation.^{70,71}

Coronary revascularization following injury [H3]

The epicardium is quiescent in the adult heart, but is reactivated and expands in response to injury.^{72,73} Reactivation is associated with expression of an embryonic gene profile and recapitulation of its developmental functions, supporting repair and neovascularisation. Ablation of tcf21 positive cells in the epicardium after ventricular resection in the zebrafish led to a reduction in cardiomyocyte proliferation, delayed neovascularisation and incomplete regeneration at 30 days.⁷⁴ In adult mice, priming of the epicardium prior to injury with the small peptide thymosin β 4 (T β 4), or treatment with epicardial cell conditioned media, improves neovascularisation and functional outcomes after MI.⁷⁵⁻⁷⁷ Similarly, stimulation of the epicardium with T β 4 in the neonatal mouse can extend the temporal window for regeneration.⁷⁸

The precise mechanisms of coronary revascularisation following injury are not well defined. There is evidence to support both local proliferation of endothelial cells and a contribution from a remote stem cell source, the endothelial progenitor cell, a controversy which is discussed in detail elsewhere.⁷⁹ In the neonatal mouse heart, neovascularisation is achieved primarily by formation of large collateral arteries which bypass the ligation site. These derive from pre-existing arteries through a process of arteriogenesis, rather than arterialization of the pre-existing capillary network.⁸⁰ Clues from non-cardiac injury models (e.g. zebrafish fin and retina) suggest that neovascularisation during regeneration is dependent on classical angiogenic signalling mechanisms involving VEGFR, HIF-1, and Cxcl12.⁸¹⁻⁸³

Neovascularization is supported by the epicardium via a number of secreted factors, including retinoic acid, fibroblast growth factors, VEGF-A and SDF1.^{84,85} Blockade of Fgf signalling in zebrafish leads to a failure of EMT and neovascularisation (discussed further below), in turn leading to failed regeneration.⁷³ In the mouse, reactivation of epicardial EMT following MI contributes several cell lineages to support repair. By inducible labelling of the *Wt1* population, EPDCs have been shown to contribute to fibroblasts, myofibroblasts, smooth muscle cells and adipocytes.^{77,86} Whether the reactivated epicardium can contribute other cell types, specifically cardiomyocytes or endothelial cells, is debated. When pre-primed with exogenous T β 4, the epicardium can generate extremely limited numbers of cardiomyocytes,

but this does not occur without priming and is not seen in zebrafish regeneration.^{75,87-89}

Finally, an emerging mechanism relates to epicardial-immune cell cross-talk. The epicardium is required for seeding of the heart with tissue-resident macrophages during embryonic development, and macrophages colocalise with the epicardium following injury.⁹⁰ Recently, the epicardium has been shown to mediate an immunosuppressive response to MI via modulation of cytokines which promote regulatory T-cell recruitment to the heart.⁹¹ In the mouse, genetic knock-out of epicardial YAP/TAZ led to persistent inflammation, widespread fibrosis, heart failure and death following MI.⁹¹

The epicardium is increasingly recognised to be a highly heterogeneous cell population containing both mesenchymal and haematopoietic cells within specialised clusters.⁹² Dissecting apart their respective roles, and separating the paracrine and progenitor cell components of the epicardial response, will require improved markers for different subpopulations. Recently at least three new subpopulations have been reported in zebrafish, including a role for novel genes such as caveolin 1.⁹³ Understanding how the epicardial response is modulated in the setting of regeneration in comparison to scar formation, for example to repress fibroblast formation, is a key research requirement in order to optimally harness its therapeutic effects.

Inflammation and immune system activation [H2]

MI leads to extensive cell death and is a potent activator of inflammation.⁹⁴ In mice and humans, inflammation is linked to repair through a biphasic immune response: an early pro-inflammatory phase characterised by release of cytokines and recruitment of neutrophils and monocytes, followed by a reparative phase with resolution of inflammation, activation of myofibroblasts and deposition of collagen-based scar.^{95,96} This process is patterned and under tight spatiotemporal regulation. Macrophages, for example, have diverse functions through the course of injury including pro-inflammatory cytokine production, phagocytosis of necrotic cell debris, pro-angiogenic signalling, activation of fibroblasts and remodelling of the ECM.^{97,98} Improved cell surface markers and transcriptional profiling are helping to define the

identity and function of specific monocyte-macrophage, neutrophil and T cell subsets in the injured heart.⁹⁹⁻¹⁰¹

Inflammation is not a barrier to tissue regeneration and in fact may provide the initial pro-regenerative cues. In the zebrafish, for example, brain injury activates acute inflammation which is sufficient to drive neural proliferation via leukotriene C4.¹⁰² The cellular immune response to injury has also been directly implicated in healing by regeneration.¹⁰³ In regenerating muscle, infiltrating cells including macrophages, eosinophils and T-regulatory cells influence activation of satellite cells and fibroadipogenic progenitors to specify production of new myofibres.^{104,105 106} Macrophages also commit endothelial progenitors to capillary formation, suppressing an alternative EMT pathway.¹⁰⁷ After liver injury, macrophage secretion of Wnt3a controls lineage differentiation of hepatic progenitor cells to produce hepatocytes.¹⁰⁸ Similarly, macrophage production of Wnt7b in the injured kidney is required for regeneration.¹⁰⁹

Inflammation and the immune response has also been linked to heart regeneration. Activation of inflammation stimulates cardiomyocyte proliferation in the neonatal heart, and blockade of IL6 or cardiomyocyte STAT3, its downstream effector, blocks heart regeneration after apical resection.¹¹⁰ In the neonatal MI model, macrophages are actively recruited to the neonatal heart and treatment with clodronate liposomes to ablate macrophages blocks regeneration through inhibition of angiogenesis.¹¹¹ Divergent roles for distinct macrophage subsets are emerging, notably between tissue-resident macrophages, seeded to visceral organs during embryonic development, in comparison to those which derive from circulating monocytes, from bone marrow or splenic reservoirs, during acute inflammation. Using a cardiomyocyte-ablation model, Lavine *et al* found that depletion of resident macrophages in the neonatal heart led to reduced cardiomyocyte and endothelial cell proliferation, interstitial fibrosis and chamber dilatation.¹¹² In contrast, inhibition of CCR2+ macrophages, derived from monocytes, preserved embryonic subsets and improved myocardial repair.¹¹²

Multiple injury models suggest that inflammatory signalling is required as a trigger to induce

cell proliferation or differentiation of progenitors to restore the lost tissue substrate. The precise mechanisms behind the divergent outcome of inflammation in regeneration and scar forming models, however, remain to be fully elucidated. The capacity for tissue regeneration appears to be inversely correlated with evolutionary complexity of the immune system, which has led to the suggestion that a component of the mammalian immune response might be a barrier to regeneration.¹¹³ Dissecting apart pro-regenerative signals from those which drive fibrosis or scar deposition, or the mechanisms by which the same signals drive divergent healing, will require detailed comparisons of immune-cell signalling in regenerative and scar-forming models. In addition, further characterisation of the interplay between immune cell subsets, fibroblasts, endothelial cells and cardiomyocytes is required. Potential therapeutic approaches to harness the regenerative potential of inflammation are discussed below.

Role of the extracellular matrix [H2]

The extracellular matrix (ECM) consists of an organised and dynamic meshwork of proteins.¹¹⁴ Previously thought of as an inert structural scaffold, the ECM is now recognised to have a number of biological effects and influences cell proliferation, migration, lineage specification, intercellular signalling and growth factor presentation.¹¹⁵ Control of the extracellular matrix is a critical component of regeneration. In the newt limb, upregulation of ECM-remodelling matrix metalloproteinases (MMPs) occurs within hours, and inhibition of MMPs blocks regeneration.¹¹⁶ This is associated with early deposition of a primitive ECM consisting of hyaluronic acid, fibronectin and tenascin-C, and downregulation of collagen.¹¹⁷ Production and remodelling of ECM components also occurs in scar-based healing, but this 'scarring' ECM is compositionally distinct and appears to be directed by immune-cell control of fibroblasts to produce collagen.¹¹⁸

In the heart, differences in ECM structure may be an important aspect underlying the interspecies capacity for regeneration. While fish have a non-compacted, spongy myocardium designed to function at low arterial blood pressure, the 4-chambered adult mammalian heart is highly compacted in a rigid matrix.¹¹⁹ In the neonatal mouse, stiffening and maturation of the ECM is correlated with cardiomyocyte cell cycle arrest and *in vitro*, modulation of ECM compliance directly influences the ability of cardiomyocytes to undergo proliferation and cytokinesis.¹²⁰ Interestingly, if the failing human heart is off-loaded by implantation of a left ventricular assist device, cell cycle re-entry has been observed – an effect which might be mediated by permissive ECM changes.¹²¹

The ECM also has direct biological effects on cardiomyocytes. The decellularised zebrafish ECM can induce cardiomyocyte proliferation and cardioprotection in the mouse heart, an effect which is mediated via the ErbB2 receptor.¹²² Functional ECM components are emerging from candidate approaches and unbiased screens. Fibronectin, derived from the epicardium after injury, stimulates zebrafish heart regeneration.^{123,124} Periostin, a matricellular protein, promotes cell cycle activation in mononucleated cardiomyocytes, but also activates fibroblasts.¹²⁵ Small and large animal studies of periostin have shown improved healing after

MI, but at the expense of increased fibrosis.^{126,127} Hyaluronic acid and its receptor hyaluronan-mediated motility receptor are required for EMT and zebrafish regeneration.¹²⁸

The roles of the ECM during regeneration and scar formation are still emerging, and thus much of the work is descriptive and early stage. The compositional differences in the ECM during regeneration and scar formation, and the biological activity of these proteins on downstream cell types, are not yet fully defined. Transcriptional profiling of fibroblasts, the major source of ECM components, and mass spectrometry of the ECM in regeneration versus scar formation, would begin to address these questions. It remains unclear to what extent ECM components can drive regeneration *in vivo* in an otherwise non-regenerative environment, and whether the ECM represents a standalone therapeutic target in endogenous regeneration. Harnessing the biological effects of the ECM is also of value to cell therapy strategies, where survival, localisation, and engraftment of cells may be augmented using patches or bioscaffolds with engineered matrix properties.¹²⁹

Scar formation and degradation [H2]

Regeneration and scar formation lie at opposite ends of the spectrum of repair. From an evolutionary perspective, it is unclear whether regenerative capacity was lost accidentally, as a neutral trait, or whether it was selected against. While it seems intuitive that regeneration would confer a survival and reproductive advantage, costs associated with energy, time or interim function (e.g. electrical stability) may have made it advantageous to heal by rapid scar formation^{130,131}

Following acute MI, scar is rapidly laid down in the mammalian heart by activated myofibroblasts. In the short term this scar is critical to providing mechanical strength and prevention of ventricular rupture. Fibroblasts are originally derived from the epicardium and endocardium during embryonic development through EMT.¹³² Using a periostin inducible Cre line for lineage tracing, Kanisicak *et al* showed that activated myofibroblasts derive from tissue-resident (tcf21+) fibroblasts, producing large quantities of extracellular matrix components such as collagen, and deactivating following resolution of injury.¹³³ In the

reparative phase, fibroblast activation following MI is multifactorial but intricately linked to macrophage cytokine regulation, for example by TGF β and CTGF. Interestingly, TGF β has been identified as a key pro-regenerative cytokine in the axolotl – but the mechanisms by which fibroblast activation are suppressed are not clear.¹³⁴

The relationship between scar deposition and regeneration is complex. It has been proposed that these two events are diametrically opposed and compete in order to achieve organ repair, with collagen deposition directly inhibitory to regeneration.¹³⁵ However, knock-down of scar formation by astrocytes following spinal cord injury is not sufficient to induce axonal regrowth.¹³⁶ Furthermore, in the cryoinjury model in the zebrafish heart, even despite extensive scar deposition during the first 3 weeks following injury, regeneration still occurs, with progressive scar removal and replacement with cardiomyocytes over time.¹⁹ The finding that scar is not necessarily a barrier to regeneration has enormous therapeutic implications, and suggests that the regenerative program does not necessarily need to be established in the early injury phase.

Strategies for therapeutic regeneration [H1]

Efforts towards heart regeneration encompass a broad spectrum of approaches including cell therapy, biomaterials, tissue engineering, reprogramming, and modulation of endogenous repair (Figure 3a). This section will focus primarily on therapeutic strategies which exploit insights from developmental biology, including specification or programming of the cardiomyocyte lineage, and endogenous regeneration.

It should be noted that distinct approaches will be required for patients post-MI and patients with chronic HF. MI provides a dynamic environment of repair in which endogenous pathways can be modulated towards regeneration. In contrast, in the setting of stable HF, strategies to directly provide new cardiomyocytes should be the focus. Current and future strategies for production of new cardiomyocytes and targeting of endogenous repair are discussed in turn (Figure 3a, b).

Cardiomyocyte replacement [H2]

Activation of cardiomyocyte proliferation [H3]

Initial attempts to reactivate cardiomyocyte proliferation were inspired by insights into cell cycle regulation by the cyclin and cyclin-dependent kinase (Cdk) system.³⁶ Cyclin-Cdk complexes modulate members of the retinoblastoma gene family (Rb, p107, p130), which in turn lead to release of E2F transcription factors which activate genes for DNA synthesis. Overexpression of cyclin B1-CDC2¹³⁷ or knockdown of the cyclin-dependent kinase inhibitors p21, p27 and p57 by RNA interference, are effective at inducing DNA replication *in vitro*.¹³⁸ *In vivo*, overexpression of cyclin A2, D1 or D2 stimulates DNA synthesis, and cyclin D2 overexpression leads to improved repair following MI.^{139,140} Other approaches have included knockout of tumour suppressor genes Rb (Rb1) and p130, and direct targeting of the E2F transcription factor family.¹⁴¹ Combinatorial reprogramming of cardiomyocytes informed by microarray approaches to define the proliferative state have proved to be more effective at achieving improved repair.¹⁴² In general, however, these approaches have triggered relatively modest DNA replication, very limited cytokinesis and consequently little new cardiomyocyte mass.

Therapeutic targeting of upstream signalling pathways regulating proliferation may reduce the risk of teratogenicity which is inherent in directly targeting the cell cycle. For example, exogenous injection of NRG1 activates proliferation of mononucleated cardiomyocytes via the ErbB4 tyrosine kinase receptor and PI3K, leading to improved repair following experimental MI.⁵⁵ Similarly, delivery of FGF1 with blockade of the p38 MAPK pathway, a key mediator of cardiomyocyte differentiation, promotes myocardial repair following injury.¹⁴³ A recent porcine MI study showed that percutaneous intramyocardial injection of microparticles loaded with NRG1 and FGF1 is effective at inducing improvement in LV function following MI, with reduced remodelling and improved angiogenesis (Table 2).¹⁴⁴ However, the growth response is exquisitely regulated: in the zebrafish, Notch activation is required for cardiomyocyte proliferation, but hyperactivation of Notch inhibited rather than promoted heart regeneration.¹⁴⁵ A phase I study of recombinant Neuregulin 1 β 3 (cimaglermin alfa) in patients with chronic heart failure has recently shown early promise, with evidence for safety and preliminary findings suggesting an improvement in LV function at 90 days (Table 3).¹⁴⁶

Therapeutic cardiomyocyte proliferation can also be induced by micro-RNA targeting. Screening of a whole genome miRNA library, identified 40 miRNAs which increased both DNA synthesis and cytokinesis *in vitro*, two of which, ~~has~~-miR-590 and ~~has~~-miR-199a, stimulated cardiac regeneration in adult mice after experimental MI.¹⁴⁷ Similarly, overexpression of the miR302-367 family is sufficient to improve regeneration following adult MI, acting via repression of the Hippo pathway.¹⁴⁸ In contrast, the miR-15 family is upregulated post-natally, correlating with the shutdown of cardiomyocyte proliferative capacity. Delivery of anti-miR15 led to increased proliferation in both the cardiomyocyte and non-myocyte compartments after MI at day 21, resulting in significant improvement in functional outcome.²¹

A major outstanding challenge in the field is that reactivation of the cardiomyocyte cell cycle is frequently not followed by completion of cytokinesis to generate new daughter cells. Identifying therapeutic factors, miRNAs or small compounds which can drive bona fide cytokinesis would benefit greatly from improved readouts of completed cell division. Efforts

towards this include the anilin-GFP model which provides a potential mechanism for discriminating cytokinesis from endoreduplication.¹⁴⁹ Despite these recent advances, accurately quantifying dividing cardiomyocytes within the adult mammalian heart is extremely difficult and would benefit greatly from further research focus.

De novo cardiomyocytes by cellular (re)programming [H3]

Production of *de novo* cardiomyocytes by directed differentiation of embryonic stem (ES) cells, or reprogramming of differentiated non-myocyte cells (e.g. fibroblasts) to a cardiomyocyte fate has revolutionised therapeutic approaches to regeneration.^{26,150}

Interestingly, reprogramming by transdifferentiation is a strategy deployed in endogenous regeneration, first recognised in the newt lens over 100 years ago.¹⁵¹ The zebrafish utilises transdifferentiation of alpha to beta cells to regenerate its islets, and in the heart can reprogram atrial to ventricular cardiomyocytes after injury.^{152,153} Reprogramming of hepatocytes to biliary endothelial cells has been described in murine liver regeneration.¹⁵⁴

Large numbers of human cardiomyocytes can be produced by differentiation of ES cells. Chong *et al* demonstrated that transplanted hESC-CMs (at a dose of 1×10^9 per heart) survive and contribute new myocardium to the macaque heart after direct injection two weeks following MI.¹⁵⁵ Although a powerful proof of concept, evidence of functional improvement was lacking and ventricular arrhythmias were recorded in all animals, suggesting that significant hurdles with electrical integration remain before human trials could safely be undertaken (Table 2). Furthermore, ethical concerns exist about use of embryonic tissue, and as an allogeneic product, recipients would require lifelong immunosuppression to prevent rejection of the cells.

Reprogramming of fibroblasts to cardiomyocytes offers potential advantages: a non-immunogenic cell product, derived from the patient's own cells, and no requirement for the destruction of embryos. Inspired by the revolutionary description of induced pluripotency by Yamanaka, reprogramming approaches were initially undertaken *ex vivo*, relying on an intermediate induced pluripotent stem (iPS) cell stage.¹⁵⁶ Transplanting iPS-derived

cardiomyocytes in a non-human primate model, Shiba *et al* showed improvement in function following cell transplant, but also a significant ventricular arrhythmia rate (Table 2).¹⁵⁷ However, production of an autologous cell product is expensive, subject to variability, and has restricted commercial opportunity. In addition to biological hurdles, the logistical and financial barriers to clinical use of autologous cell therapies are extremely challenging. Current cell numbers in the macaque trials have been of the order of 10^8 - 10^9 cells, with at least an order of magnitude higher required for humans. The infrastructure and running costs of good manufacturing production at this scale, ideally embedded within or close to clinical cardiac centres, appear prohibitive.

The discovery that delivery of three cardiac developmental transcription factors, Gata4, Mef2c and Tbx5 could drive direct reprogramming of fibroblasts into cardiomyocytes, without an intermediate cell stage, has opened the door to the concept of reprogramming *in vivo*.^{158,159} A number of additional factors which improve the efficiency of reprogramming have now been identified, most notably Hand2.¹⁶⁰ This approach requires no cell product, obviating the need for complex manufacturing. Proof of concept for *in vivo* reprogramming has now been demonstrated in mice, with transdifferentiated cells expressing sarcomeric proteins, forming gap junctions, and driving sustained improvement in ventricular function.¹⁶¹⁻¹⁶⁴ Substantial challenges remain, including achieving selectivity of targeting to cardiomyocytes, reprogramming human cells which have stable epigenetic modifications, and achieving maturation of structure and function in reprogrammed cells.

Neovascularisation & lymphangiogenesis [H2]

Strategies aimed at neovascularisation in MI have been somewhat frustrated in recent years by the failed promise of vascular endothelial growth factor (VEGF-A). Despite a number of animal studies showing efficacy from the recombinant protein or gene therapy with VEGF-A, the double blind EUROINJECT-ONE and NORTHERN clinical trials failed to show benefit.^{165,166} Attempting to reactivate more comprehensive developmental programs of coronary vessel formation, including targeting retained adult cell types that previously contributed to the developing coronaries, including the coronary sinus (sinus venosus-

derived), endocardium and epicardium is a more attractive strategy for invoking neovascularization post-MI.

The epicardium in particular has emerged as a viable target and the development of *in vitro* systems for culture of human epicardium from human pluripotent stem cells will facilitate both biological understanding of the heterogeneity of the epicardium and small molecule screening for activating compounds.¹⁶⁷ Recently, epicardial FSTL1 was identified as a key anti-apoptotic and proliferative factor promoting myocardial regeneration after injury. Application of a patch containing recombinant human FSTL1 improved long-term cardiac function in both rodent and swine models of myocardial infarction (Table 2).¹⁶⁸ Furthermore, Zangi *et al* showed that intracardiac injection of a modified RNA (modRNA) encoding VEGF-A led to enhanced epicardial progenitor activation and improved functional outcome after MI.¹⁶⁹ Functionally, VEGF-A modRNA promoted differentiation of EPDCs towards an endothelial (and in small numbers cardiomyocyte) cell fate.¹⁶⁹

Clinical translation would benefit greatly from the ability to image the epicardium *in vivo*, and emerging technologies using PET, SPECT and molecular imaging to demonstrate angiogenesis will guide future trials.¹⁷⁰ The endocardium continues to provide further endothelium for vessel formation for a short period during postnatal growth and might be reactivated in adulthood to enhance neovascularisation.¹⁷¹ Interestingly, experimental MI in mice has recently been shown to activate endothelial remodelling on the endocardial surface, leading to outgrowth of pre-existing coronary vessels and *de novo* arteriogenesis.¹⁷²

Stimulation of new lymphatic vessel formation, lymphangiogenesis, is another emerging strategy to augment repair. The cardiac lymphatics remain poorly understood but are important for transport of interstitial fluid and trafficking of immune cells.¹⁷³ Following MI, endogenous repair mechanisms activate lymphangiogenesis in mice and humans, a response which is required for clearance of oedema and resolution of inflammation.¹⁷⁴ In rodents, augmentation of lymphangiogenesis by stimulation of VEGF-C signalling, the principal cytokine mediator of lymphatic formation during development, improves healing,

reduces fibrosis and preserves myocardial function.^{175,176} The precise mechanisms underlying this are poorly understood but may relate to clearance of oedema and resolution of inflammation.

Immunomodulation [H2]

Components of functional pathways, which can loosely be termed “inflammation”, are intricately linked to healing following MI. A number of unsuccessful clinical trials of immunosuppressive agents (e.g. methylprednisolone, immunoglobulin, pexelizumab, anakinra; see Table 3) suggest that blunt inhibition of inflammation is not effective.¹⁷⁷ Successful immunomodulation is likely to require both more nuance stratification of patients based on known activation (or inhibition) of specific pathways, coupled with identification and successful *in vivo* targeting of specific immune cell subsets, or pathways, to bring about beneficial repair. For example, inhibition of the CCR2+ monocyte population mobilised after MI using nanoparticle-delivered anti-CCR2 siRNA led to reduced injury and cardiac remodelling in mice.¹⁷⁸ Transplantation of specific immune cell populations is a strategy being tested in other diseases: autologous macrophages are being trialled for regression of liver fibrosis¹⁷⁹, and infusion of T-regulatory cells has shown efficacy in reduction of inflammation. Furthermore, understanding the differences of the immune response in the setting of scar formation compared to regeneration will shed light on precise pathways which can be modulated to enhance regeneration without compromising repair. In the chronic HF patient, immunomodulation is unlikely to be sufficient to induce regeneration. However, immunosuppression or induction of tolerance will be required to prevent rejection of allogeneic cardiomyocyte cell therapies, or vectors used to deliver a reprogramming cocktail.

Fibrosis inhibition [H2]

Inhibition of pro-fibrotic signalling in the setting of chronic HF has been suggested to account for some of the existing benefits of beta-blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers and statins. A number of novel anti-fibrotic compounds are emerging and have recently been reviewed in the context of cardiovascular disease.¹⁸⁰ Inhibition of scar formation after MI may have a complementary role to stimulation of endogenous repair or cell therapy, but without effective replacement of cardiomyocytes, remains critical to prevent cardiac rupture. Targeting late ‘reactive’ fibrosis in the uninjured myocardium, however, may reduce ventricular remodelling and progression to heart failure.¹⁸¹

For example, in addition to its effects on cardiomyocyte proliferation, NRG1 administered between 7-35 days following MI reduced fibrosis and remodelling in swine through inhibition of myofibroblast transdifferentiation and TGF β signalling.¹⁸² Inhibition of chymase, which stimulates fibroblast activation after injury, reduced fibrotic area and improved survival following MI in small animal models.^{183,184} In rats, blockade of platelet derived growth factor (PDGF) receptor signalling with imatinib selectively inhibited fibrosis in the non-infarcted myocardium.¹⁸⁵ Other prospective anti-fibrotic strategies in early stage studies include inhibitors of Wnt and histone deacetylases, and modulation of relaxin signalling (Figure 3b).¹⁸⁰ Prior to clinical trials in humans, an improved understanding of the heterogeneity of human post-MI healing is required, to allow targeting of anti-fibrotic therapies to groups at highest risk. For example, the use of advanced imaging and novel biomarkers of inflammation and fibrosis in the early phase of MI may identify outlier patient subpopulations who could then be targeted with specific therapies.

Translational challenges and considerations [H1]

The last decade of clinical cell therapy trials have provided important lessons for the design and translation of future regenerative therapies.^{186,187} Issues related to the use of animal models, drug discovery approaches, patient selection, and clinical trial design will be discussed in turn.

Limitations of animal models [H2]

Animal models have unquestionable value as a route to novel biological insights, and there is extensive species conservation in regenerative signalling pathways such as Notch, TGF β , and JAK/STAT.¹⁸⁸ From a translational perspective, however, there is a pressing need to improve the filtering of therapeutic targets and compounds prior to human studies. Many recent clinical trials of compounds targeting cardiac repair have shown limited efficacy (Table 3) and this has led to questions regarding the validity of animal models for assessing novel therapeutic strategies.

For regenerative therapies, a key problem inherent to existing animal studies is the use of young, healthy, homogeneous populations which lack the comorbidities or drug confounders typically associated with human patients. Age is inversely correlated with capacity for repair, with older mice demonstrating impaired wound healing after MI.¹⁸⁹ In young animals, the 'bar' to improved repair is low, leading to false positive results and subsequent failed large animal or human studies. Development of highly *non-regenerative* animal models, such as aged rodents or pigs, might help reduce false positive studies prior to human trials.

Drug discovery [H2]

Focused drug discovery approaches to cardiac regeneration are complicated by the breadth of therapeutic strategies which persist in the academic arena, ranging from cell replacement, to reprogramming, to stimulation of endogenous regeneration (Table 2; Figure 3a). To address this, a move towards use of phenotypic screens, *in vivo* discovery and combination approaches will be required, with underlying biological insights used for target deconvolution. For example, screening for cardiomyocyte cell cycle reactivation *in vivo* using the FUCCI

fluorescent reporter in zebrafish has been used to identify compounds targeting the Hedgehog, insulin-like growth factor and TGF β pathways which effectively stimulate cell cycle re-entry.¹⁹⁰ Furthermore, the 'FunSel' screening approach, whereby a cDNA library of the mouse secretome is targeted to cardiomyocytes *in vivo* using an adenoviral vector, has been applied to identify cardioprotective factors.¹⁹¹ Targeted sequencing to identify factors which are enriched after MI revealed that cardiomyocytes transfected with ghrelin improved cell survival after injury.

Once novel screening systems are established, partnerships with pharma should be established early in order to access screening libraries and improve the process of lead generation and optimization. Many paradigms which are effective *in vitro* or in pre-clinical models may of course fail to translate into the clinic. Assessment of compounds across multiple assays, or screening to assess the cumulative benefit of targeting of multiple parallel pathways for a given endpoint (for example, cardiomyocyte proliferation) may result in improved clinical efficacy downstream.^{192,193}

Delivery systems for regenerative therapies [H2]

Targeting the heart is achievable through a combination of local delivery, biomaterial adjuncts and biological selectivity. For delivery, advances in catheter technology have made transendocardial injection, subepicardial access and intracoronary injection available by percutaneous, minimally-invasive approach.¹⁹⁴ Surgical approaches by median sternotomy may be reasonable for proof of principle but are not realistic for the frail, comorbid HF population at large. Alongside delivery, major advances have been made in the field of biomaterials and bioscaffolds.¹²⁹ Pre-seeded scaffolds, patches or injectable hydrogels have been shown to improve retention and survival of transplanted cells.¹⁹⁵ For non-cell based approaches, delivery of factors within hydrogels or coated on microparticles can prevent rapid clearance or degradation.¹⁹⁶ Local delivery and retention must be complemented by biological targeting (e.g. targeted liposomes, exosomes, or viral vectors) or biological selectivity for cardiomyocyte pathways. The risks of off-target effects are greatest for pro-proliferative or reprogramming approaches, which may disrupt remote cell function or be tumorigenic.¹⁹⁷

Patient selection [H2]

Targeting therapies to selected patient groups will be key to the success of future regenerative therapy trials. Two distinct groups with separate biological and logistical challenges are patients with acute MI and patients with chronic HF.

The acute MI population is attractive for regenerative therapies which modulate or harness existing repair pathways, for example factors to promote cardiomyocyte proliferation or angiogenesis, epicardial targeting, immunomodulation or inhibition of fibrosis. The gain from such therapies might be expected to be greatest in young patients without comorbidities, in whom the barrier to endogenous regeneration is lowest. However, identifying precisely which MI patients to target is difficult as accurate predictors of future HF are lacking. Although age, diabetes, coronary physiology or imaging parameters (e.g. oedema, haemorrhage or microvascular obstruction) are predictors of final infarct size in cohorts at large, it remains difficult to accurately predict future HF events for a given patient. Practically, this means it may be difficult to justify the use of the highest-risk interventions (e.g. cell reprogramming) in patients.

Better identification of patients at risk of HF is required: emerging possibilities for enhanced characterisation derive from novel, mechanistically relevant biomarkers, including exosome characterisation, miRNA profiling and cellular transcriptomics.⁹⁴ The goal is to develop diagnostics that provide quantifiable data on therapeutically relevant targets, which can be used to recruit patients to specific therapies. As noted in the cancer field, it seems likely that optimal characterisation will require approaches that combine imaging and panels of biomarkers for mechanistic staging.

In patients with chronic HF, the disease is established and in those with severely impaired left ventricular function and NYHA III-IV symptoms, the prognosis is extremely poor. As such, regenerative strategies which carry higher risk may be reasonable. Implantable cardioverter defibrillators are already indicated in this patient group to protect from arrhythmia and

therefore cardiomyocyte cell therapy, reprogramming or cell patches, which may be arrhythmogenic, should be targeted at this cohort. The subgroup of patients on LVAD therapy as a bridge to heart transplant should also be recruited, as cardiac tissue may become available (at heart transplantation) to examine biological endpoints such as cell engraftment.

Clinical trial design [H2]

Regenerative therapies require re-evaluation of their clinical trial paradigm.¹⁹⁸ Early trials of cell therapies have been small, heterogeneous, and subject to small study effect, in which subsequent studies fail to reproduce an apparently large effect. Improvements in trial design, particularly at the phase II stage, have the potential to reduce this problem.¹⁹⁹ Wherever possible, phase II clinical studies should be designed to demonstrate a defined biological effect as a surrogate for efficacy. This might include angiogenesis, evidence of engraftment, or cell cycle re-entry, and in turn needs development and validation of novel imaging strategies for regeneration.²⁰⁰ This key step would allow biological insights to be correlated with clinical outcomes, in order to prioritise some therapies for large-scale, placebo controlled trials. These should ideally be carried out as part of consensus regenerative medicine networks such as the Cardiovascular Cell Therapy Research Network, which has been instrumental in organising large studies to show that BMMNCs in acute MI or ischaemic cardiomyopathy do not improve LV function. Furthermore, there is increasing recognition of reporting issues with cell therapy trials, with over 600 reporting discrepancies identified across 49 trials.²⁰¹ Of concern, the number of discrepancies correlated with the reported effect size in the trial. There is a need for standardization of cell characterisation, handling, methodology and reporting practice (akin to PRISMA or CONSORT) for trials.

Conclusions

Novel regenerative therapies inspire great hope amongst patients, scientists, physicians and the media. Although this excitement can be warranted, it can easily lead to exaggeration of actual benefits. Balancing the needs of a desperate patient population with the requirements for scientific rigour is challenging. Guidelines from the International Society for Stem Cell Research specifically warn against the dangers of hype as novel therapies emerge.^{202,203}

Progress with regenerative therapies is likely to be incremental and iterative rather than a quantum leap.

While complete regeneration of the infarcted heart is the end goal, marginal gains in cardiomyocyte number, neovascularisation or scar reduction are a realistic first step and would have therapeutic value. The emerging biology of endogenous regeneration and cardiomyocyte biology is exposing a multiplicity of therapeutic targets which might be exploited by conventional small molecule approaches, recombinant factors, microRNAs, reprogramming or cell transplantation.

Improving the commercialisation of regenerative therapies requires closer partnership of scientists, spin-outs, pharmaceutical industry and clinical trialists. There is a role for pharma in early partnership with scientists to test compound libraries in novel *in vitro* or *in vivo* screens. Improved pre-clinical models, patient selection and design of early clinical studies to establish biological efficacy in human subjects will help streamline a next generation of regenerative therapy trials. At the national level, governmental support is required, through facilitation of regulation and funding for incubator/facilitator organisations such as the Cell Therapy Catapult (U.K.) and the Centre for Commercialization of Regenerative Medicine (Canada) and CellCAN in Canada.²³⁰

REFERENCES

1. Roger, V.L. Epidemiology of Heart Failure. *Circulation Research* **113**, 646 (2013).
2. Cahill, T.J., Ashrafian, H. & Watkins, H. Genetic cardiomyopathies causing heart failure. *Circ Res* **113**, 660-675 (2013).
3. Braunwald, E. The war against heart failure: the Lancet lecture. *The Lancet* **385**, 812-824 (2015).
4. Velagaleti, R.S., *et al.* Long-Term Trends in the Incidence of Heart Failure After Myocardial Infarction. *Circulation* **118**, 2057 (2008).
5. Ezekowitz, J.A., *et al.* Declining In-Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction. *Journal of the American College of Cardiology* **53**, 13-20 (2009).
6. Heidenreich, P.A., *et al.* Forecasting the Impact of Heart Failure in the United States. *Circulation: Heart Failure* **6**, 606 (2013).
7. Katz, A.M. The “Modern” View of Heart Failure. *Circulation: Heart Failure* **1**, 63 (2008).
8. Jhund, P.S. & McMurray, J.J.V. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. *Heart* **102**, 1342 (2016).
9. Kloner, R.A. Current State of Clinical Translation of Cardioprotective Agents for Acute Myocardial Infarction. *Circulation Research* **113**, 451 (2013).
10. Nguyen, P.K., Rhee, J. & Wu, J.C. Adult stem cell therapy and heart failure, 2000 to 2016: A systematic review. *JAMA Cardiology* **1**, 831-841 (2016).
11. Yester, J.W. & Kühn, B. Mechanisms of Cardiomyocyte Proliferation and Differentiation in Development and Regeneration. *Current Cardiology Reports* **19**, 13 (2017).
12. Karra, R. & Poss, K.D. Redirecting cardiac growth mechanisms for therapeutic regeneration. *The Journal of Clinical Investigation* **127**, 427-436 (2017).
13. Vivien, C.J., Hudson, J.E. & Porrello, E.R. Evolution, comparative biology and ontogeny of vertebrate heart regeneration. *Regenerative Medicine* **1**, 16012 (2016).
14. Gonzalez-Rosa, J.M. & Mercader, N. Cryoinjury as a myocardial infarction model for the study of cardiac regeneration in the zebrafish. *Nat. Protocols* **7**, 782-788 (2012).
15. Wang, J., *et al.* The regenerative capacity of zebrafish reverses cardiac failure caused by genetic cardiomyocyte depletion. *Development* **138**, 3421 (2011).
16. Parente, V., *et al.* Hypoxia/Reoxygenation Cardiac Injury and Regeneration in Zebrafish Adult Heart. *PLOS ONE* **8**, e53748 (2013).
17. Poss, K.D., Wilson, L.G. & Keating, M.T. Heart Regeneration in Zebrafish. *Science* **298**, 2188 (2002).

First definitive report of heart regeneration

18. Witman, N., Murtuza, B., Davis, B., Arner, A. & Morrison, J.I. Recapitulation of developmental cardiogenesis governs the morphological and functional regeneration of adult newt hearts following injury. *Developmental biology* **354**, 67-76 (2011).
19. González-Rosa, J.M., Martín, V., Peralta, M., Torres, M. & Mercader, N. Extensive scar formation and regression during heart regeneration after cryoinjury in zebrafish. *Development* **138**, 1663 (2011).
20. Porrello, E.R., *et al.* Transient Regenerative Potential of the Neonatal Mouse Heart. *Science* **331**, 1078-1080 (2011).

First report of mammalian heart regeneration

21. Porrello, E.R., *et al.* Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. *Proceedings of the National Academy of Sciences* **110**, 187-192 (2013).
22. Haubner, B.J., *et al.* Functional Recovery of a Human Neonatal Heart After Severe Myocardial Infarction. *Circulation Research* (2015).
23. Fratz, S., *et al.* Long-Term Myocardial Scarring After Operation for Anomalous Left Coronary Artery From the Pulmonary Artery. *The Annals of Thoracic Surgery* **92**, 1761-1765 (2011).
24. Tsang, V., *et al.* Late donor cardiectomy after paediatric heterotopic cardiac transplantation. *The Lancet* **374**, 387-392.
25. Carlson, B.M. Some principles of regeneration in mammalian systems. *The Anatomical Record Part B: The New Anatomist* **287B**, 4-13 (2005).
26. Xin, M., Olson, E.N. & Bassel-Duby, R. Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair. *Nat Rev Mol Cell Biol* **14**, 529-541 (2013).
27. Kretzschmar, K. & Watt, Fiona M. Lineage Tracing. *Cell* **148**, 33-45.
28. Jopling, C., *et al.* Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. *Nature* **464**, 606-609 (2010).

New cardiomyocytes in the regenerating heart are derived from the existing cardiomyocyte pool

29. Kikuchi, K., *et al.* Primary contribution to zebrafish heart regeneration by gata4+ cardiomyocytes. *Nature* **464**, 601-605 (2010).

New cardiomyocytes in the regenerating heart are derived from the existing cardiomyocyte pool

30. Senyo, S.E., *et al.* Mammalian heart renewal by pre-existing cardiomyocytes. *Nature* **493**, 433-436 (2013).
31. Ellison, Georgina M., *et al.* Adult c-kit+ Cardiac Stem Cells Are Necessary and Sufficient for Functional Cardiac Regeneration and Repair. *Cell* **154**, 827-842.
32. van Berlo, J.H. & Molkentin, J.D. An emerging consensus on cardiac regeneration. *Nat Med* **20**, 1386-1393 (2014).
33. Orlic, D., *et al.* Bone marrow cells regenerate infarcted myocardium. *Nature* **410**, 701-705 (2001).

34. Murry, C.E., *et al.* Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. *Nature* **428**, 664-668 (2004).

Landmark study refuting the concept of bone marrow-derived progenitor cells as a source of new cardiomyocytes in the mouse

35. Balsam, L.B., *et al.* Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. *Nature* **428**, 668-673 (2004).
36. Ahuja, P., Sdek, P. & MacLellan, W.R. Cardiac Myocyte Cell Cycle Control in Development, Disease, and Regeneration. *Physiological reviews* **87**, 521 (2007).
37. Bergmann, O., *et al.* Evidence for Cardiomyocyte Renewal in Humans. *Science* **324**, 98 (2009).

Identification and quantification of cardiomyocyte replication in the human heart using carbon-14 dating

38. Mollova, M., *et al.* Cardiomyocyte proliferation contributes to heart growth in young humans. *Proceedings of the National Academy of Sciences* **110**, 1446-1451 (2013).
39. Puente, Bao N., *et al.* The Oxygen-Rich Postnatal Environment Induces Cardiomyocyte Cell-Cycle Arrest through DNA Damage Response. *Cell* **157**, 565-579 (2014).
40. Kimura, W., *et al.* Hypoxia fate mapping identifies cycling cardiomyocytes in the adult heart. *Nature* **523**, 226-230 (2015).
41. Engel, F.B., *et al.* p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. *Genes & Development* **19**, 1175-1187 (2005).
42. Mahmoud, A.I., *et al.* Meis1 regulates postnatal cardiomyocyte cell cycle arrest. *Nature* **497**, 249-253 (2013).

Identification of Meis1 as an inhibitor of the cardiomyocyte cell cycle

43. Lee, K.-F., *et al.* Requirement for neuregulin receptor erbB2 in neural and cardiac development. *Nature* **378**, 394-398 (1995).
44. Gassmann, M., *et al.* Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. *Nature* **378**, 390-394 (1995).
45. Gemberling, M., Karra, R., Dickson, A.L. & Poss, K.D. Nrg1 is an injury-induced cardiomyocyte mitogen for the endogenous heart regeneration program in zebrafish. *eLife* **4**, e05871 (2015).
46. Yelon, D., *et al.* The bHLH transcription factor hand2 plays parallel roles in zebrafish heart and pectoral fin development. *Development* **127**, 2573 (2000).
47. Srivastava, D., *et al.* Regulation of cardiac mesodermal and neural crest development by the bHLH transcription factor, dHAND. *Nat Genet* **16**, 154-160 (1997).
48. Schindler, Y.L., *et al.* Hand2 elevates cardiomyocyte production during zebrafish heart development and regeneration. *Development* **141**, 3112 (2014).
49. Yu, W., *et al.* GATA4 regulates Fgf16 to promote heart repair after injury. *Development* **143**, 936 (2016).
50. Zhou, Q., Li, L., Zhao, B. & Guan, K.-L. The Hippo Pathway in Heart Development,

Regeneration, and Diseases. *Circulation Research* **116**, 1431 (2015).

51. Heallen, T., *et al.* Hippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size. *Science* **332**, 458 (2011).

Identification of the Hippo pathway as a key mediator of cardiomyocyte proliferation

52. Xin, M., *et al.* Hippo pathway effector Yap promotes cardiac regeneration. *Proceedings of the National Academy of Sciences* **110**, 13839-13844 (2013).
53. Hang, C.T., *et al.* Chromatin regulation by Brg1 underlies heart muscle development and disease. *Nature* **466**, 62-67 (2010).
54. Xiao, C., *et al.* Chromatin-remodelling factor Brg1 regulates myocardial proliferation and regeneration in zebrafish. *Nature communications* **7**, 13787 (2016).
55. Bersell, K., Arab, S., Haring, B. & Kühn, B. Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury. *Cell* **138**, 257-270 (2009).
56. Gupta, V. & Poss, K.D. Clonally dominant cardiomyocytes direct heart morphogenesis. *Nature* **484**, 479-484 (2012).
57. Kubin, T., *et al.* Oncostatin M Is a Major Mediator of Cardiomyocyte Dedifferentiation and Remodeling. *Cell Stem Cell* **9**, 420-432 (2011).
58. Di Talia, S. & Poss, Kenneth D. Monitoring Tissue Regeneration at Single-Cell Resolution. *Cell Stem Cell* **19**, 428-431 (2016).
59. Walsh, S., Pontén, A., Fleischmann, B.K. & Jovinge, S. Cardiomyocyte cell cycle control and growth estimation in vivo—an analysis based on cardiomyocyte nuclei. *Cardiovascular Research* **86**, 365-373 (2010).
60. White, I.A., Gordon, J., Balkan, W. & Hare, J.M. Sympathetic Reinnervation Is Required for Mammalian Cardiac Regeneration. *Circulation Research* **117**, 990 (2015).
61. Mahmoud, A.I., *et al.* Nerves Regulate Cardiomyocyte Proliferation and Heart Regeneration. *Developmental cell* **34**, 387-399 (2015).
62. Regenfus, M., *et al.* Six-Year Prognostic Value of Microvascular Obstruction After Reperfused ST-Elevation Myocardial Infarction as Assessed by Contrast-Enhanced Cardiovascular Magnetic Resonance. *The American Journal of Cardiology* **116**, 1022-1027 (2015).

63. Red-Horse, K., Ueno, H., Weissman, I.L. & Krasnow, M.A. Coronary arteries form by developmental reprogramming of venous cells. *Nature* **464**, 549-553 (2010).

Coronary vessels originate from the sinus venosus during development

64. Tian, X., *et al.* Subepicardial endothelial cells invade the embryonic ventricle wall to form coronary arteries. *Cell Res* **23**, 1075-1090 (2013).
65. Zhang, H., *et al.* Endocardium Minimally Contributes to Coronary Endothelium in the Embryonic Ventricular Free Walls. *Circulation Research* **118**, 1880-1893 (2016).
66. Masters, M. & Riley, P.R. The epicardium signals the way towards heart regeneration. *Stem Cell Research* **13**, 683-692 (2014).

67. Risebro, C.A., Vieira, J.M., Klotz, L. & Riley, P.R. Characterisation of the human embryonic and foetal epicardium during heart development. *Development* **142**, 3630 (2015).
68. Katz, T.C., *et al.* Distinct Compartments of the Proepicardial Organ Give Rise to Coronary Vascular Endothelial Cells. *Developmental cell* **22**, 639-650 (2012).
69. Tian, X., Pu, W.T. & Zhou, B. Cellular Origin and Developmental Program of Coronary Angiogenesis. *Circ Res* **116**, 515-530 (2015).
70. von Gise, A., *et al.* WT1 regulates epicardial epithelial to mesenchymal transition through β -catenin and retinoic acid signaling pathways. *Developmental biology* **356**, 421-431 (2011).
71. Kwee, L., *et al.* Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. *Development* **121**, 489-503 (1995).
72. Huang, G.N., *et al.* C/EBP Transcription Factors Mediate Epicardial Activation During Heart Development and Injury. *Science* **338**, 1599 (2012).
73. Lepilina, A., *et al.* A Dynamic Epicardial Injury Response Supports Progenitor Cell Activity during Zebrafish Heart Regeneration. *Cell* **127**, 607-619 (2006).
74. Wang, J., Cao, J., Dickson, A.L. & Poss, K.D. Epicardial regeneration is guided by cardiac outflow tract and Hedgehog signalling. *Nature* **522**, 226-230 (2015).
75. Smart, N., *et al.* De novo cardiomyocytes from within the activated adult heart after injury. *Nature* **474**, 640-644 (2011).
76. Smart, N., *et al.* Thymosin beta 4 induces adult epicardial progenitor mobilization and neovascularization. *Nature* **445**, 177-182 (2007).
77. Zhou, B., *et al.* Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. *The Journal of Clinical Investigation* **121**, 1894-1904 (2011).
78. Rui, L., *et al.* Extending the time window of mammalian heart regeneration by thymosin beta 4. *Journal of Cellular and Molecular Medicine* **18**, 2417-2424 (2014).
79. Hagensen, M.K., Vanhoutte, P.M. & Bentzon, J.F. Arterial endothelial cells: still the craftsmen of regenerated endothelium. *Cardiovascular Research* **95**, 281 (2012).
80. He, L., *et al.* Genetic lineage tracing discloses arteriogenesis as the main mechanism for collateral growth in the mouse heart. *Cardiovascular Research* **109**, 419 (2016).
81. Bayliss, P.E., *et al.* Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish. *Nat Chem Biol* **2**, 265-273 (2006).
82. Eyries, M., *et al.* Hypoxia-Induced Apelin Expression Regulates Endothelial Cell Proliferation and Regenerative Angiogenesis. *Circulation Research* **103**, 432 (2008).
83. Xu, C., *et al.* Arteries are formed by vein-derived endothelial tip cells. *Nature communications* **5**, 5758 (2014).
84. Zhou, B., *et al.* Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. *The Journal of Clinical Investigation* **121**, 1894-1904.
85. Kikuchi, K., *et al.* Retinoic Acid Production by Endocardium and Epicardium Is an Injury Response Essential for Zebrafish Heart Regeneration. *Developmental cell* **20**,

397-404 (2011).

86. Zangi, L., *et al.* An IGF1R-Dependent Pathway Drives Epicardial Adipose Tissue Formation After Myocardial Injury. *Circulation* (2016).
87. Zhou, B., *et al.* Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes. *Journal of Molecular and Cellular Cardiology* **52**, 43-47 (2012).
88. Kikuchi, K., *et al.* tcf21+ epicardial cells adopt non-myocardial fates during zebrafish heart development and regeneration. *Development* (2011).
89. González-Rosa, J.M., Peralta, M. & Mercader, N. Pan-epicardial lineage tracing reveals that epicardium derived cells give rise to myofibroblasts and perivascular cells during zebrafish heart regeneration. *Developmental biology* **370**, 173-186 (2012).
90. Stevens, S.M., Gise, A.v., VanDusen, N., Zhou, B. & Pu, W.T. Epicardium is required for cardiac seeding by yolk sac macrophages, precursors of resident macrophages of the adult heart. *Developmental biology* **413**, 153-159 (2016).
91. Ramjee, V., *et al.* Epicardial YAP/TAZ orchestrate an immunosuppressive response following myocardial infarction. *The Journal of Clinical Investigation* **127**, 899-911 (2017).
92. Balmer, G.M., *et al.* Dynamic haematopoietic cell contribution to the developing and adult epicardium. *Nature communications* **5**, 4054 (2014).
93. Cao, J., *et al.* Single epicardial cell transcriptome sequencing identifies Caveolin 1 as an essential factor in zebrafish heart regeneration. *Development* **143**, 232 (2016).
94. Ruparelia, N., *et al.* Acute myocardial infarction activates distinct inflammation and proliferation pathways in circulating monocytes, prior to recruitment, and identified through conserved transcriptional responses in mice and humans. *European Heart Journal* **36**, 1923-1934 (2015).
95. Frangogiannis, N.G. Regulation of the Inflammatory Response in Cardiac Repair. *Circulation Research* **110**, 159-173 (2012).
96. Nahrendorf, M., *et al.* The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. *The Journal of Experimental Medicine* **204**, 3037-3047 (2007).
97. Nahrendorf, M. & Swirski, F.K. Abandoning M1/M2 for a Network Model of Macrophage Function. *Circ Res* **119**, 414-417 (2016).
98. Shiraishi, M., *et al.* Alternatively activated macrophages determine repair of the infarcted adult murine heart. *The Journal of Clinical Investigation* **126**, 2151-2166 (2016).
99. Zouggar, Y., *et al.* B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. *Nat Med* **19**, 1273-1280 (2013).
100. Weirather, J., *et al.* Foxp3+ CD4+ T Cells Improve Healing After Myocardial Infarction by Modulating Monocyte/Macrophage Differentiation. *Circulation Research* **115**, 55-67 (2014).
101. Ma, Y., *et al.* Temporal neutrophil polarization following myocardial infarction. *Cardiovascular Research* **110**, 51 (2016).

102. Kyritsis, N., *et al.* Acute Inflammation Initiates the Regenerative Response in the Adult Zebrafish Brain. *Science* **338**, 1353 (2012).

Inflammation is sufficient to initiate regeneration in the zebrafish brain

103. Karin, M. & Clevers, H. Reparative inflammation takes charge of tissue regeneration. *Nature* **529**, 307-315 (2016).
104. Aurora, Arin B. & Olson, Eric N. Immune Modulation of Stem Cells and Regeneration. *Cell Stem Cell* **15**, 14-25 (2014).
105. Burzyn, D., *et al.* A Special Population of Regulatory T Cells Potentiates Muscle Repair. *Cell* **155**, 1282-1295.
106. Heredia, Jose E., *et al.* Type 2 Innate Signals Stimulate Fibro/Adipogenic Progenitors to Facilitate Muscle Regeneration. *Cell* **153**, 376-388 (2013).
107. Zordan, P., *et al.* Macrophages commit postnatal endothelium-derived progenitors to angiogenesis and restrict endothelial to mesenchymal transition during muscle regeneration. *Cell death & disease* **5**, e1031 (2014).
108. Boulter, L., *et al.* Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. *Nat Med* **18**, 572-579 (2012).
109. Lin, S.-L., *et al.* Macrophage Wnt7b is critical for kidney repair and regeneration. *Proceedings of the National Academy of Sciences* **107**, 4194-4199 (2010).
110. Han, C., *et al.* Acute inflammation stimulates a regenerative response in the neonatal mouse heart. *Cell Res* **25**, 1137-1151 (2015).
111. Aurora, A.B., *et al.* Macrophages are required for neonatal heart regeneration. *The Journal of Clinical Investigation* **124**, 1382-1392 (2014).

Macrophages are essential for regeneration in the neonatal mouse heart by modulation of neoangiogenesis

112. Lavine, K.J., *et al.* Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. *Proceedings of the National Academy of Sciences* **111**, 16029-16034 (2014).
113. Godwin, J.W. & Brockes, J.P. Regeneration, tissue injury and the immune response. *Journal of Anatomy* **209**, 423-432 (2006).
114. Rienks, M., Papageorgiou, A.-P., Frangogiannis, N.G. & Heymans, S. Myocardial Extracellular Matrix. *Circulation Research* **114**, 872 (2014).
115. Bonnans, C., Chou, J. & Werb, Z. Remodelling the extracellular matrix in development and disease. *Nat Rev Mol Cell Biol* **15**, 786-801 (2014).
116. Vinarsky, V., Atkinson, D.L., Stevenson, T.J., Keating, M.T. & Odelberg, S.J. Normal newt limb regeneration requires matrix metalloproteinase function. *Developmental biology* **279**, 86-98 (2005).
117. Calve, S., Odelberg, S.J. & Simon, H.-G. A transitional extracellular matrix instructs cell behavior during muscle regeneration. *Developmental biology* **344**, 259-271 (2010).
118. Godwin, J.W. & Rosenthal, N. Scar-free wound healing and regeneration in amphibians: Immunological influences on regenerative success. *Differentiation* **87**,

66-75 (2014).

119. Hu, N., Yost, H.J. & Clark, E.B. Cardiac morphology and blood pressure in the adult zebrafish. *The Anatomical Record* **264**, 1-12 (2001).
120. Yahalom-Ronen, Y., Rajchman, D., Sarig, R., Geiger, B. & Tzahor, E. Reduced matrix rigidity promotes neonatal cardiomyocyte dedifferentiation, proliferation and clonal expansion. *eLife* **4**, e07455 (2015).
121. Canseco, D.C., *et al.* Human Ventricular Unloading Induces Cardiomyocyte Proliferation. *Journal of the American College of Cardiology* **65**, 892-900 (2015).
122. Chen, W.C.W., *et al.* Decellularized zebrafish cardiac extracellular matrix induces mammalian heart regeneration. *Science Advances* **2**, e1600844 (2016).
123. Mercer, S.E., Odelberg, S.J. & Simon, H.-G. A dynamic spatiotemporal extracellular matrix facilitates epicardial-mediated vertebrate heart regeneration. *Developmental biology* **382**, 457-469 (2013).
124. Wang, J., Karra, R., Dickson, A.L. & Poss, K.D. Fibronectin is deposited by injury-activated epicardial cells and is necessary for zebrafish heart regeneration. *Developmental biology* **382**, 427-435 (2013).
125. Shimazaki, M., *et al.* Periostin is essential for cardiac healing after acute myocardial infarction. *The Journal of Experimental Medicine* **205**, 295 (2008).
126. Kuhn, B., *et al.* Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. *Nat Med* **13**, 962-969 (2007).
127. Ladage, D., *et al.* Stimulating Myocardial Regeneration with Periostin Peptide in Large Mammals Improves Function Post-Myocardial Infarction but Increases Myocardial Fibrosis. *PLOS ONE* **8**, e59656 (2013).
128. Yang, E.V., Gardiner, D.M., Carlson, M.R.J., Nugas, C.A. & Bryant, S.V. Expression of Mmp-9 and related matrix metalloproteinase genes during axolotl limb regeneration. *Developmental Dynamics* **216**, 2-9 (1999).
129. Hastings, C.L., *et al.* Drug and cell delivery for cardiac regeneration. *Advanced Drug Delivery Reviews* **84**, 85-106 (2015).
130. Bely, A.E. & Nyberg, K.G. Evolution of animal regeneration: re-emergence of a field. *Trends in Ecology & Evolution* **25**, 161-170 (2010).
131. Goss, R.J. The evolution of regeneration: Adaptive or inherent? *Journal of Theoretical Biology* **159**, 241-260 (1992).
132. Furtado, M.B., Nim, H.T., Boyd, S.E. & Rosenthal, N.A. View from the heart: cardiac fibroblasts in development, scarring and regeneration. *Development* **143**, 387 (2016).
133. Kanisicak, O., *et al.* Genetic lineage tracing defines myofibroblast origin and function in the injured heart. *Nature communications* **7**, 12260 (2016).
134. Lévesque, M., *et al.* Transforming Growth Factor: β Signaling Is Essential for Limb Regeneration in Axolotls. *PLOS ONE* **2**, e1227 (2007).
135. Satoh, A., Hirata, A. & Makanae, A. Collagen Reconstitution is Inversely Correlated with Induction of Limb Regeneration in *Ambystoma mexicanum*. *Zoological Science* **29**, 191-197 (2012).

136. Anderson, M.A., *et al.* Astrocyte scar formation aids central nervous system axon regeneration. *Nature* **532**, 195-200 (2016).
137. Bicknell, Katrina A., Coxon, Carmen H. & Brooks, G. Forced expression of the cyclin B1–CDC2 complex induces proliferation in adult rat cardiomyocytes. *Biochemical Journal* **382**, 411 (2004).
138. Di Stefano, V., Giacca, M., Capogrossi, M.C., Crescenzi, M. & Martelli, F. Knockdown of Cyclin-dependent Kinase Inhibitors Induces Cardiomyocyte Re-entry in the Cell Cycle. *Journal of Biological Chemistry* **286**, 8644-8654 (2011).
139. Chaudhry, H.W., *et al.* Cyclin A2 Mediates Cardiomyocyte Mitosis in the Postmitotic Myocardium. *Journal of Biological Chemistry* **279**, 35858-35866 (2004).
140. Pasumarthi, K.B.S., Nakajima, H., Nakajima, H.O., Soonpaa, M.H. & Field, L.J. Targeted Expression of Cyclin D2 Results in Cardiomyocyte DNA Synthesis and Infarct Regression in Transgenic Mice. *Circulation Research* **96**, 110 (2005).
141. Ebelt, H., *et al.* E2F2 expression induces proliferation of terminally differentiated cardiomyocytes in vivo. *Cardiovascular Research* **80**, 219 (2008).
142. Cheng, Y.Y., *et al.* Reprogramming- derived gene cocktail increases cardiomyocyte proliferation for heart regeneration. *EMBO molecular medicine* (2016).
143. Engel, F.B., Hsieh, P.C.H., Lee, R.T. & Keating, M.T. FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. *Proceedings of the National Academy of Sciences* **103**, 15546-15551 (2006).
144. Garbayo, E., *et al.* Catheter-based Intramyocardial Injection of FGF1 or NRG1-loaded MPs Improves Cardiac Function in a Preclinical Model of Ischemia-Reperfusion. *Scientific Reports* **6**, 25932 (2016).
145. Zhao, L., *et al.* Notch signaling regulates cardiomyocyte proliferation during zebrafish heart regeneration. *Proceedings of the National Academy of Sciences* **111**, 1403-1408 (2014).
146. Lenihan, D.J., *et al.* A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1 β 3) in Patients With Systolic Dysfunction and Heart Failure. *JACC: Basic to Translational Science* **1**, 576-586 (2016).
147. Eulalio, A., *et al.* Functional screening identifies miRNAs inducing cardiac regeneration. *Nature* **492**, 376-381 (2012).

MicroRNAs are involved in cardiac regeneration and have therapeutic effects to modulate repair in the mouse heart

148. Tian, Y., *et al.* A microRNA-Hippo pathway that promotes cardiomyocyte proliferation and cardiac regeneration in mice. *Science Translational Medicine* **7**, 279ra238 (2015).
149. Hesse, M., *et al.* Direct visualization of cell division using high-resolution imaging of M-phase of the cell cycle. *Nature communications* **3**, 1076 (2012).
150. Srivastava, D. & DeWitt, N. In Vivo Cellular Reprogramming: The Next Generation. *Cell* **166**, 1386-1396 (2016).
151. Jopling, C., Boue, S. & Belmonte, J.C.I. Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. *Nat Rev Mol Cell Biol* **12**, 79-89 (2011).

152. Thorel, F., *et al.* Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. *Nature* **464**, 1149-1154 (2010).
153. Zhang, R., *et al.* In vivo cardiac reprogramming contributes to zebrafish heart regeneration. *Nature* **498**, 497-501 (2013).
154. Yanger, K., *et al.* Robust cellular reprogramming occurs spontaneously during liver regeneration. *Genes & Development* **27**, 719-724 (2013).
155. Chong, J.J.H., *et al.* Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. *Nature* **510**, 273-277 (2014).

Human ES-derived cardiomyocytes can engraft the macaque heart following MI

156. Takahashi, K. & Yamanaka, S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell* **126**, 663-676 (2006).
157. Shiba, Y., *et al.* Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. *Nature* **538**, 388-391 (2016).
158. Efe, J.A., *et al.* Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. *Nat Cell Biol* **13**, 215-222 (2011).
159. Ieda, M., *et al.* Direct Reprogramming of Fibroblasts into Functional Cardiomyocytes by Defined Factors. *Cell* **142**, 375-386 (2010).

Fibroblasts can be directly reprogrammed into cardiomyocytes *in vitro* by Gata4, Mef2c and Tbx5

160. Srivastava, D. & Yu, P. Recent advances in direct cardiac reprogramming. *Current Opinion in Genetics & Development* **34**, 77-81 (2015).
161. Song, K., *et al.* Heart repair by reprogramming non-myocytes with cardiac transcription factors. *Nature* **485**, 599-604 (2012).

Key study demonstrating *in vivo* reprogramming to form new cardiomyocytes

162. Qian, L., *et al.* In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. *Nature* **485**, 593-598 (2012).

Key study demonstrating *in vivo* reprogramming to form new cardiomyocytes

163. Jayawardena, T.M., *et al.* MicroRNA-Mediated In Vitro and In Vivo Direct Reprogramming of Cardiac Fibroblasts to Cardiomyocytes. *Circulation Research* **110**, 1465 (2012).
164. Li, Y., *et al.* Tissue-engineered 3-dimensional (3D) microenvironment enhances the direct reprogramming of fibroblasts into cardiomyocytes by microRNAs. *Scientific Reports* **6**, 38815 (2016).
165. Taimeh, Z., Loughran, J., Birks, E.J. & Bolli, R. Vascular endothelial growth factor in heart failure. *Nature Reviews Cardiology* **10**, 519-530 (2013).
166. Giacca, M. & Zacchigna, S. VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. *Gene Ther* **19**, 622-629 (2012).
167. Iyer, D., *et al.* Robust derivation of epicardium and its differentiated smooth muscle cell progeny from human pluripotent stem cells. *Development* **142**, 1528-1541 (2015).

168. Wei, K., *et al.* Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. *Nature* **525**, 479-485 (2015).
169. Zangi, L., *et al.* Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. *Nat Biotech* **31**, 898-907 (2013).
170. Mandic, L., *et al.* Molecular Imaging of Angiogenesis in Cardiac Regeneration. *Current Cardiovascular Imaging Reports* **9**, 27 (2016).
171. Tian, X., *et al.* De novo formation of a distinct coronary vascular population in neonatal heart. *Science* **345**, 90-94 (2014).
172. Miquerol, L., *et al.* Endothelial Plasticity Drives Arterial Remodeling Within the Endocardium After Myocardial Infarction. *Circulation Research* **116**, 1765 (2015).
173. Norman, S. & Riley, P.R. Anatomy and development of the cardiac lymphatic vasculature: Its role in injury and disease. *Clinical Anatomy* **29**, 305-315 (2016).
174. Ishikawa, Y., *et al.* Lymphangiogenesis in myocardial remodelling after infarction. *Histopathology* **51**, 345-353 (2007).
175. Klotz, L., *et al.* Cardiac lymphatics are heterogeneous in origin and respond to injury. *Nature* **522**, 62-67 (2015).
176. Henri, O., *et al.* Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction. *Circulation* (2016).
177. Ruparel, N., Chai, J.T., Fisher, E.A. & Choudhury, R.P. Inflammatory processes in cardiovascular disease: a route to targeted therapies. *Nature Reviews Cardiology* **14**, 133-144 (2016).
178. Majmudar, M.D., *et al.* Monocyte-Directed RNAi Targeting CCR2 Improves Infarct Healing in Atherosclerosis-Prone Mice. *Circulation* **127**, 2038 (2013).
179. Macrophages therapy for liver cirrhosis. (BioMed Central, ISRCTN registry).
180. Gourdie, R.G., Dimmeler, S. & Kohl, P. Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease. *Nature Reviews Drug Discovery* **15**, 620-638 (2016).
181. Talman, V. & Ruskoaho, H. Cardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration. *Cell and Tissue Research* **365**, 563-581 (2016).
182. Galindo, C.L., *et al.* Anti-Remodeling and Anti-Fibrotic Effects of the Neuregulin-1 β Glial Growth Factor 2 in a Large Animal Model of Heart Failure. *Journal of the American Heart Association* **3**(2014).
183. Kanemitsu, H., *et al.* Chymase Inhibition Prevents Cardiac Fibrosis and Dysfunction after Myocardial Infarction in Rats. *Hypertens Res* **29**, 57-64 (2006).
184. Hoshino, F., *et al.* Chymase inhibitor improves survival in hamsters with myocardial infarction. *J Cardiovasc Pharmacol* **41**, S11-18 (2003).
185. Liu, C., *et al.* Platelet-derived growth factor blockade on cardiac remodeling following infarction. *Molecular and Cellular Biochemistry* **397**, 295-304 (2014).
186. Menasche, P. Cardiac cell therapy: Lessons from clinical trials. *Journal of Molecular and Cellular Cardiology* **50**, 258-265 (2011).

187. Behfar, A., Crespo-Diaz, R., Terzic, A. & Gersh, B.J. Cell therapy for cardiac repair - lessons from clinical trials. *Nature Reviews Cardiology* **11**, 232-246 (2014).
188. Alvarado, A.S. & Tsonis, P.A. Bridging the regeneration gap: genetic insights from diverse animal models. *Nat Rev Genet* **7**, 873-884 (2006).
189. Bujak, M., *et al.* Aging-Related Defects Are Associated With Adverse Cardiac Remodeling in a Mouse Model of Reperfused Myocardial Infarction. *Journal of the American College of Cardiology* **51**, 1384-1392 (2008).
190. Choi, W.-Y., *et al.* In vivo monitoring of cardiomyocyte proliferation to identify chemical modifiers of heart regeneration. *Development* **140**, 660 (2013).
191. Ruozzi, G., *et al.* AAV-mediated in vivo functional selection of tissue-protective factors against ischaemia. *Nature communications* **6**, 7388 (2015).
192. Plowright, A.T., Engkvist, O., Gill, A., Knerr, L. & Wang, Q.-D. Heart Regeneration: Opportunities and Challenges for Drug Discovery with Novel Chemical and Therapeutic Methods or Agents. *Angewandte Chemie International Edition* **53**, 4056-4075 (2014).
193. Willems, E., *et al.* A Chemical Biology Approach to Myocardial Regeneration. *Journal of Cardiovascular Translational Research* **4**, 340-350 (2011).
194. Campbell, N.G. & Suzuki, K. Cell Delivery Routes for Stem Cell Therapy to the Heart: Current and Future Approaches. *Journal of Cardiovascular Translational Research* **5**, 713-726 (2012).
195. Qian, L., *et al.* Hemodynamic contribution of stem cell scaffolding in acute injured myocardium. *Tissue Eng Part A* **18**, 1652-1663 (2012).
196. Saludas, L., Pascual-Gil, S., Prósper, F., Garbayo, E. & Blanco-Prieto, M. Hydrogel based approaches for cardiac tissue engineering. *International Journal of Pharmaceutics* (2016).
197. Sarig, R. & Tzahor, E. The cancer paradigms of mammalian regeneration: can mammals regenerate as amphibians? *Carcinogenesis* **38**, 359-366 (2017).
198. Rosen, M.R., Myerburg, R.J., Francis, D.P., Cole, G.D. & Marbán, E. Translating Stem Cell Research to Cardiac Disease Therapies: Pitfalls and Prospects for Improvement. *Journal of the American College of Cardiology* **64**, 922-937 (2014).
199. Hare, J.M., *et al.* Phase II Clinical Research Design in Cardiology. *Circulation* **127**, 1630 (2013).
200. Naumova, A.V., Modo, M., Moore, A., Murry, C.E. & Frank, J.A. Clinical imaging in regenerative medicine. *Nature biotechnology* **32**, 804-818 (2014).
201. Nowbar, A.N., *et al.* Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis. *BMJ* **348**, g2688 (2014).
202. ISSCR. Guidelines for stem cell science and clinical translation. (Skokie, IL, 2016).
203. Caulfield, T., Sipp, D., Murry, C.E., Daley, G.Q. & Kimmelman, J. Confronting stem cell hype. *Science* **352**, 776 (2016).
204. Swirski, F.K., *et al.* Identification of splenic reservoir monocytes and their deployment to inflammatory sites. *Science* **325**, 612-616 (2009).

205. Niccoli, G., Burzotta, F., Galiuto, L. & Crea, F. Myocardial No-Reflow in Humans. *Journal of the American College of Cardiology* **54**, 281-292 (2009).
206. Van Linthout, S., Miteva, K. & Tschope, C. Crosstalk between fibroblasts and inflammatory cells. *Cardiovascular Research* **102**, 258-269 (2014).
207. Pfeffer, M.A. & Braunwald, E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. *Circulation* **81**, 1161 (1990).
208. Sutton, M.G.S.J. & Sharpe, N. Left Ventricular Remodeling After Myocardial Infarction. *Circulation* **101**, 2981 (2000).
209. Packer, M. Pathophysiology of chronic heart failure. *The Lancet* **340**, 88-92 (1992).
210. Lympieropoulos, A., Rengo, G. & Koch, W.J. Adrenergic Nervous System in Heart Failure. *Circulation Research* **113**, 739 (2013).
211. Narula, J., Haider, N., Arbustini, E. & Chandrashekar, Y. Mechanisms of Disease: apoptosis in heart failure - seeing hope in death. *Nature Clinical Practice Cardiovascular Medicine* **3**, 681-688 (2006).
212. Packer, M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. *Journal of the American College of Cardiology* **20**, 248-254 (1992).
213. Menasché, P., *et al.* Myoblast transplantation for heart failure. *The Lancet* **357**, 279-280 (2001).
214. Strauer, B.E., *et al.* Repair of Infarcted Myocardium by Autologous Intracoronary Mononuclear Bone Marrow Cell Transplantation in Humans. *Circulation* **106**, 1913 (2002).
215. Perin, E.C., *et al.* Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure. *Circulation* **107**, 2294 (2003).
216. Wollert, K.C., *et al.* Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. *The Lancet* **364**, 141-148 (2004).
217. Lunde, K., *et al.* Intracoronary Injection of Mononuclear Bone Marrow Cells in Acute Myocardial Infarction. *New England Journal of Medicine* **355**, 1199-1209 (2006).
218. Schächinger, V., *et al.* Intracoronary Bone Marrow-Derived Progenitor Cells in Acute Myocardial Infarction. *New England Journal of Medicine* **355**, 1210-1221 (2006).
219. Janssens, S., *et al.* Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. *The Lancet* **367**, 113-121 (2006).
220. Menasché, P., *et al.* The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial. *Circulation* **117**, 1189 (2008).
221. Bolli, R., *et al.* Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. *The Lancet* **378**, 1847-1857 (2011).
222. Makkar, R.R., *et al.* Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. *The Lancet* **379**, 895-904 (2012).

223. Perin, E.C., Willerson, J.T., Pepine, C.J. & et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The focus-cctrn trial. *JAMA* **307**, 1717-1726 (2012).
224. Sürder, D., *et al.* Intracoronary Injection of Bone Marrow Derived Mononuclear Cells, Early or Late after Acute Myocardial Infarction: Effects on Global Left Ventricular Function Four months results of the SWISS-AMI trial. *Circulation* **127**, 1968-1979 (2013).
225. Karantalis, V., *et al.* Autologous Mesenchymal Stem Cells Produce Concordant Improvements in Regional Function, Tissue Perfusion, and Fibrotic Burden When Administered to Patients Undergoing Coronary Artery Bypass Grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. *Circulation Research* **114**, 1302-1310 (2014).
226. Menasché, P., *et al.* Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. *European Heart Journal* **36**, 2011-2017 (2015).
227. Choudry, F., *et al.* A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trial. *European Heart Journal* **37**, 256-263 (2016).
228. Bagno, L.L., *et al.* Growth Hormone–Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute Ischemic Cardiomyopathy. *Journal of the American Heart Association* **4**, e001464 (2015).
229. Koudstaal, S., *et al.* Sustained Delivery of Insulin-Like Growth Factor-1/Hepatocyte Growth Factor Stimulates Endogenous Cardiac Repair in the Chronic Infarcted Pig Heart. *Journal of Cardiovascular Translational Research* **7**, 232-241 (2014).
230. Gao, R., *et al.* A Phase II, Randomized, Double-Blind, Multicenter, Based on Standard Therapy, Placebo-Controlled Study of the Efficacy and Safety of Recombinant Human Neuregulin-1 in Patients With Chronic Heart Failure. *Journal of the American College of Cardiology* **55**, 1907-1914 (2010).
231. O'Donoghue, M.L., Glaser, R., Cavender, M.A. & et al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: A randomized clinical trial. *JAMA* **315**, 1591-1599 (2016).
232. Cerisano, G., *et al.* Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. *European Heart Journal* **35**, 184-191 (2013).
233. Abbate, A., *et al.* Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]. *The American Journal of Cardiology* **111**, 1394-1400 (2013).
234. Abbate, A., *et al.* Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study). *American Journal of Cardiology* **105**, 1371-1377.e1371.
235. Gullestad, L., *et al.* Intravenous immunoglobulin does not reduce left ventricular remodeling in patients with myocardial dysfunction during hospitalization after acute myocardial infarction. *International Journal of Cardiology* **168**, 212-218 (2013).

236. Najjar, S.S., Rao, S.V., Melloni, C. & et al. Intravenous erythropoietin in patients with st-segment elevation myocardial infarction: Reveal: a randomized controlled trial. *JAMA* **305**, 1863-1872 (2011).
237. The, A.A.M.I.I. Pexelizumab for acute st-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial. *JAMA* **297**, 43-51 (2007).
238. Hudson, M.P., et al. Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction: Results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) Trial. *Journal of the American College of Cardiology* **48**, 15-20 (2006).

Acknowledgments

T.J.C is supported by the Wellcome Trust (grant: 106334/Z/14/Z). PRR is supported by the British Heart Foundation (grants: CH/11/1/28798; RG/13/9/303269).

Conflict of interest statement

None to declare

Boxes

Box 1: Development of heart failure: pathophysiological mechanisms

Heart failure following acute MI is a paradigm for failed regeneration. Following coronary artery occlusion, ischaemic death of cardiomyocytes begins within hours. Cell injury and death trigger release of proinflammatory cytokines, infiltration of neutrophils and mobilisation of monocytes from the spleen.²⁰⁴ Opening of the occluded coronary artery by PPCI improves salvage of the injured myocardium, but in the short term leads to a burst of oxidative stress and further cardiomyocyte death. Even after reperfusion, microvascular obstruction (caused by thrombotic and plaque debris and by endothelial damage) persists in up to 50% of patients.²⁰⁵ Over subsequent days, inflammation drives further infarct expansion at the border zones. A transition from inflammation to repair is characterised by activation of fibroblasts to myofibroblasts, which deposit collagen matrix leading to scar formation.²⁰⁶

Chronic remodelling of the damaged left ventricle subsequently occurs over weeks to months, with ventricular dilatation, scar thinning and activation of interstitial fibrosis.^{207,208} Reduced cardiac output triggers activation of neurohormonal systems which act to maintain the circulation.²⁰⁹ Release of angiotensin II and aldosterone drive sodium and fluid retention, and adrenergic system activation maintains blood pressure through vasoconstriction.²¹⁰ These mechanisms are initially compensatory but become maladaptive, driving fluid overload, myocardial hypertrophy, and slow but ongoing cardiomyocyte death, leading to further deterioration in ventricular function.^{211,212} Incremental benefits may be gained by optimising early salvage, no-reflow and further inhibition of maladaptive physiology, but entirely novel approaches are required to address the fundamental issue of cardiomyocyte death.

Figure Legends

Figure 1

Heart failure therapy pipeline, to present day. In green: landmark breakthroughs in heart failure therapy, with key trials indicated by *. In purple: progress in regenerative therapies for heart failure. Abbreviations: ACEI – angiotensin converting enzyme inhibitors; ARB – angiotensin receptor blockers; BB – beta-blockers; BMMCs – bone marrow mononuclear cells; CMs – cardiomyocytes; ES – embryonic stem cell; CRT – cardiac resynchronisation therapy; HF – heart failure; ICD – implantable cardioverter defibrillator; iPS – induced pluripotent stem cell; MRA – mineralocorticoid receptor antagonists; MSCs – mesenchymal stem cells.

Figure 2

Endogenous mechanisms controlling cardiomyocyte proliferation. Initiation of cardiomyocyte proliferation is regulated by both intrinsic and extrinsic factors. A number of soluble ligands have been identified which promote cardiomyocyte proliferation during development and in models of heart regeneration, including NRG1, FGF1, antagonists of Hippo, Wnts and TWEAK. Other soluble cues implicated in proliferation include OSM1, a macrophage-derived cytokine which directs cardiomyocyte de-differentiation. Downstream transcriptional regulators of cardiomyocyte cell-cycle re-entry include Hand2, Gata4, YAP/TAZ, Hif1 α and miRNAs. In the adult mammalian heart, cardiomyocytes exit the cell cycle postnatally and are resistant to cell cycle re-entry, with proliferation inhibited by p38MAPK, Meis1, miR15 and reactive oxygen species. Structural and functional aspects of the extracellular matrix also regulate cardiomyocyte proliferation: periostin and a lack of matrix rigidity promote cardiomyocyte proliferation. Factors which promote cytokinesis following binucleation, to generate new daughter cells, remain poorly defined.

Figure 3

Therapeutic strategies for heart regeneration

a) Strategies for replacement of cardiomyocytes (CMs). From top: (1) Reactivation of cardiomyocyte proliferation is the major mechanism by which endogenous regeneration

occurs in the zebrafish and neonatal mouse, and has been achieved in preclinical models by targeting upstream ligands such as NRG1 and FGF1, and downstream cell cycle pathways mediated by Meis1, YAP/TAZ, p38MAPK, and miRNAs including ~~has~~-miR-590, ~~has~~-miR-199a, and miR302-367. (2) Stimulation of progenitor populations such as the epicardium or cardiac progenitor cells (CPCs) leads to pleiotropic effects to support CM survival and proliferation, but current strategies do not appear to directly lead to new CMs in significant numbers. (3) *In vivo* reprogramming of fibroblast to produce CMs has been achieved in preclinical models using defined transcription factor cocktails (e.g. GHMT) and microRNAs, and *in vitro* by small molecules. (4). Replacement of CMs by transplantation of exogenous mature CMs, derived from iPS cells or ES cells, have shown proof of concept in large animal studies.

b) Therapeutic targeting of the non-cardiomyocyte compartment for cardiac regeneration. (1) Epicardial activation (top right). During cardiac development and after injury, soluble factors derived from the activated epicardium supports angiogenesis, cardiomyocyte proliferation and survival, including FSTL1, FGF2 and VEGFa. Identifying factors (such as TB4) which activate or direct the epicardium to promote repair, or delivery of specific recombinant factors identified from the epicardium, are unexploited therapeutic strategies. (2) Angiogenesis (red vessels)/lymphangiogenesis (green vessels). Replacement of damaged vasculature will be vital to support new survival of transplanted, reprogrammed or proliferated CMs. Delivery of recombinant VEGFc, a macrophage-derived cytokine which promotes lymphangiogenesis, improves healing and functional outcome following MI in mice. (3) Immunomodulation (bottom right): inhibition of CCL2/CCR2 signalling in monocyte-macrophages by delivery of siRNA nanoparticles reduces monocyte infiltration and infarct size in mice. Signals from the epicardium have recently been identified which recruit regulatory T cells to dampen inflammation following injury. (4) Fibrosis: (left): harnessing endogenous anti-fibrotic pathways mediated by NRG1 or relaxin may be harnessed to halt progression of remodelling and heart failure. Targeting pro-fibrotic pathways with inhibitors of PDGFR, Wnts, chymase or HDAC, have all shown promise in small animal models. Finally, *in vivo* reprogramming of fibroblasts into CMs, using GATA4, Hand2, Mef2c and Tbx5, may allow replacement of CMs, restoration of function and prevent fibrosis. Current therapeutic strategies shown in green,

solid lines; endogenous signalling pathways shown in orange, dotted lines.

Table 1: Landmark studies from the infancy of regeneration: cell therapy trials in acute myocardial infarction & heart failure

Name	Design	Patient group/no.	Cell type/dose/delivery route	Primary endpoint	Outcome(s)	Comment	Ref
Menasche <i>et al</i> 2001	Case report	Ischaemic HF undergoing CABG n = 1	Skeletal myoblasts 800 x 10 ⁶ cells Intramyocardial injection during CABG	NA	NA	First-in-man report of skeletal myoblast injection. Improved wall motion and perfusion on PET	213
Strauer <i>et al</i> 2002	Non-randomised Open label	Acute MI n = 20	Autologous BM cells 2.8 x 10 ⁷ cells Intracoronary delivery	Not specified	Reduced infarct size in cell therapy arm	First study of BM cells in acute MI	214
Perin <i>et al</i> 2003	Non-randomised Open label	Ischaemic HF n = 21	Autologous BM mononuclear cells Mean 25.5 ± 6.3 x 10 ⁶ cells Transendocardial injection	Safety	Improved LV function, reduced reversible perfusion defect	First study of BM cells in HF	215
BOOST 2004	Randomised Non-placebo controlled	Acute MI n = 60	Autologous BM cells 24.6 x 10 ⁶ nucleated cells Intracoronary delivery	Change in LVEF	Improved global LV function	First randomised study of BM cells	216
ASTAMI 2006	Randomised Non-placebo controlled	Acute MI n = 100	Autologous BM mononuclear cells Median 68 x 10 ⁶ cells Intracoronary delivery	Change in LVEF	No change in LVEF or LVEDV or IS at 6 months	Negative trial concurrent with REPAIR-AMI	217
REPAIR-AMI 2006	Randomised Double blind Placebo controlled	Acute MI n = 204	Autologous BM progenitor cells 236 x 10 ⁶ cells Intracoronary delivery	Change in LVEF	Significant improvement in global LV function at 4 months	Largest trial of BMCs. Showed reduction in clinical endpoint of death, recurrent MI & revasc	218
Janssens <i>et al</i> 2006	Randomised Double blind Placebo controlled	Acute MI n = 67	Autologous BM stem cells 304 x 10 ⁶ nucleated cells Intracoronary delivery	Change in LVEF	Negative for primary endpoint	Reduction in infarct volume	219
MAGIC 2008	Randomised Double blind Placebo controlled	HF & previous MI undergoing CABG n = 97	Skeletal myoblasts 400 (low dose) – 800 (high dose) x 10 ⁶ cells Surgical injection during CABG	Change in regional and global LV function	Negative for primary efficacy endpoints	High cell dose arm had reduced LV remodelling with decreased LV volumes. Increased arrhythmias in the cell therapy arms.	220
SCIPIO* 2011	Randomised Open label Non-placebo controlled	Ischaemic HF n = 23	Autologous c-kit+ cardiac stem cells 1 x 10 ⁶ cells Intracoronary delivery	Safety	No adverse events reported	Increase in LVEF and decrease in infarct size reported in cell therapy recipients (secondary endpoints)	221
CADUCEUS 2012	Randomised Non-placebo controlled	Acute MI n = 25	Cardiosphere-derived cells 12.5-25 x 10 ⁶ cells Intracoronary delivery	Safety: arrhythmic or unexpected death, MI, tumour formation or MACE	Met safety endpoint	Reduction in scar size/mass in cell therapy arm	222
FOCUS-CCRTN 2012	Randomised Double blind Placebo controlled	Ischaemic HF n = 92	Autologous BM stem cells 100 x 10 ⁶ cells Transendocardial injection	Change in LV end-systolic volume; maximal O2 consumption, reversibility on SPECT	Negative for primary endpoints		223
SWISS-AMI 2013	Randomised Open label Non-placebo controlled	Acute MI n = 200	Autologous BM mononuclear cells 140-160 x 10 ⁶ nucleated cells Intracoronary delivery either early (5-7 days) or late (3-4 weeks) after MI	Change in LVEF	Negative for primary endpoint		224
PROMETHEUS 2014	Non-randomised Non-placebo controlled	Ischaemic HF undergoing CABG n = 6	Mesenchymal stem cells 2 x 10 ⁷ (low dose) - 2 x 10 ⁸ (high dose) cells Intramyocardial injection during CABG	NA	NA	Increased EF, decreased scar mass	225
Menasche <i>et al.</i> 2015	Case report	Ischaemic HF undergoing CABG n = 1	Human ES-derived cardiac progenitor cells on a fibrin scaffold Surgical patch implantation	NA	NA	First in man study. New onset contractility observed in the patched region	226
REGENERATE-AMI 2016	Randomised Double blind Placebo controlled	Acute MI n = 100	Autologous BM-derived cells 59.8 x 10 ⁶ cells Intracoronary delivery	Change in LVEF	Negative for primary endpoint	Large, double-blinded study of autologous BM cells which failed to meet primary efficacy endpoint	227

Abbreviations: BM – bone marrow; ES – embryonic stem; CABG – coronary artery bypass grafting; HF – heart failure; LVEF – left ventricular ejection fraction; MACE – major adverse cardiovascular events; NA – not applicable; PET – positron emission tomography, SPECT - single-photon emission computed tomography; * subject to expression of concern

Table 2: Translational pipeline: preclinical large animal regeneration studies in heart failure following myocardial infarction

Drug/therapy	Mechanism	Model/Delivery	Outcome	Comment	Ref
Human ES-derived CMs	Direct CM replacement	HF (2 weeks post-I/R) Surgical intramyocardial injection	Successful transplantation, electromechanical integration and partial maturation of ES-derived CMs No significant change in LVEF	First study to demonstrate regeneration by transplantation of CMs. All transplanted animals experienced ventricular arrhythmias	¹⁵⁵
Allogeneic iPS-derived CMs	Direct CM replacement	HF (2 weeks post-I/R) Surgical intramyocardial injection	Significant improvement in LVEF (~10%) at 12 weeks	Proof of principle study. All transplanted animals experienced sustained ventricular tachycardia peaking at day 14 post-transplantation	¹⁵⁷
FGF1 & NRG1-loaded microparticles	Angiogenesis Reversal of fibrosis	HF (4 weeks post-I/R) Catheter-based transendocardial injection	Approximate 8-10% improvement in fractional shortening with both NRG1 & FGF1 microparticles	Reduced ventricular remodelling observed	¹⁴⁴
MR- 409 (GHRH agonist)	Pleiotropic effects Activation of the GH/IGF-1 axis	HF (2 weeks post-I/R) Subcutaneous injection	Reduced scar size after 4 weeks	Not accompanied by improved cardiac function	²²⁸
Recombinant FSTL1 in patch	Pleiotropic effects Stimulation of CM proliferation Arteriogenesis	HF (1 week post I/R) Surgical patch implantation	Approximate 10% improvement in LVEF		¹⁶⁸
IGF1 & HGF within hydrogel	Stimulation of CM proliferation Angiogenesis	HF (4 weeks post-I/R) Catheter-based transendocardial injection	Small improvement in LVEF Reduced scar formation	Overall small functional effects observed; trend towards reduced fibrosis	²²⁹

Abbreviations: ES – embryonic stem (cell); I/R – ischaemia/reperfusion; LVEF – left ventricular ejection fraction; GHRH – growth hormone releasing hormone; GH – growth hormone; HGF – hepatocyte growth factor; IGF-1 – insulin-like growth factor 1; iPS – induced pluripotent (stem cell); CM – cardiomyocyte

Table 3: Recent clinical trials targeting cardiac injury and repair after acute myocardial infarction

Trial	Drug	Mechanism	Phase/ Patient cohort	Primary Endpoint(s)	Outcome	Ref
Lenihan <i>et al</i> 2016	Cimaglermin- α	Recombinant full length neuregulin 1 β 3	Phase I 40 patients with symptomatic HF and LVEF \leq 40%. HF aetiology not reported	Safety/tolerability	No severe adverse effects. Improvement in LVEF in the high-dose groups (~7-9%) lasting for study duration (90 days)	¹⁴⁶
Gao <i>et al</i> 2010	Neucardin	Recombinant epidermal growth factor-like domain of neuregulin-1 β	Phase II 44 patients with symptomatic HF and LVEF \leq 40%. HF aetiology not reported	Change in LVEF, end-systolic volume, or end-diastolic volume at 90 days	Non-significant trend towards improved LVEF and reduced LV remodelling in the neuregulin arms	²³⁰
LATITUDE-TIMI 60	Losmapimod	p38 MAP kinase inhibitor	Phase III 3503 patients with ACS	Major adverse cardiovascular events at 24 weeks	No significant difference in primary endpoint or HF events	²³¹
TIPTOP	Doxycycline	Oral MMP inhibitor	Phase II 110 patients with STEMI	Change in LVEDVI at 6 months	Significant reduction in LVEDVI and infarct size with doxycycline	²³²
VCU-ART2	Anakinra	IL1-receptor antagonist	Phase II 30 patients with STEMI	Change in LVESVI at ~ 3 months	No significant change in LVESVI, LVEDVI or LVEF. Combined data from VCU-ART2 & VCU-ART suggested a reduction in HF events in the anakinra arm. Larger trial (VCU-ART3) currently recruiting	²³³
VCU-ART	Anakinra	IL1-receptor antagonist	Phase II pilot 10 patients with STEMI	Change in LVESVI at ~ 3 months	Significant improvement in LVESVI on cardiac MRI	²³⁴
Gullestad <i>et al</i> 2013	IVIG	Immunomodulation	Phase II 62 STEMI patients	Change in LVEF at 6 months	No significant difference in change in LVEF or scar size	²³⁵
REVEAL	Erythropoietin	Pleiotropic effects on injury/repair	Phase II 222 patients with STEMI	Infarct size	No significant difference in infarct size. Increased rate of adverse events with erythropoietin.	²³⁶
APEX AMI	Pexelizumab	Humanised monoclonal antibody neutralising C5 component of complement	Phase III 5,745 patients with STEMI	All-cause mortality at 30 days	No significant difference in mortality, or in secondary composite endpoint of death, shock or HF at 30 and 90 days	²³⁷
PREMIER	PG-116800	Oral MMP inhibitor	Phase II 253 patients with STEMI & impaired LV function (LVEF 15-40%)	Change in LVEDVI at 90 days	No significant difference in LVEDVI after 30 or 90 days	²³⁸

Abbreviations: ACS – acute coronary syndrome; CMs – cardiomyocytes; HF – heart failure; LVEF – left ventricular ejection fraction; iPS – induced pluripotent (stem cell); LVEDVI – left ventricular end-diastolic volume index; LVESVI – left ventricular end-systolic volume index; MI – myocardial infarction; MMP – matrix metalloproteinase; PCI – percutaneous coronary intervention; STEMI – ST-elevation myocardial infarction

Glossary:

Autologous: derived from cells/tissues of the same individual

Allogeneic: derived from genetically different individuals from the same species

Binucleation: division of the nucleus leading to formation of two nuclei within a cell, without division of the cytoplasm

Cytokinesis: division of the cell cytoplasm to complete the cell cycle and create a membrane barrier between two daughter cells

Embryonic stem (ES) cells: pluripotent stem cells that are derived from the inner cell mass of human embryos

Epicardium: the outer layer of the heart, also known as the visceral pericardium

Fibrosis: a pathological process characterised by deposition of interstitial fibrous or scar tissue

Heart failure: a pathological state defined by the inability of the heart to pump blood to support the requirements of the body. Typical symptoms include shortness of breath, fluid retention and fatigue

Induced pluripotent stem (iPS) cells: pluripotent stem cells that are reprogrammed from somatic cells by introducing pluripotency factors

Lymphangiogenesis: the growth of new lymphatic vessels

Ploidy: the number of sets of chromosomes in a cell

Myocardial infarction (heart attack): acute injury to the heart caused by occlusion of the coronary blood supply, usually due to atherosclerotic plaque rupture

Remodelling: a process characterised by a change in size, shape and structure of the ventricle. After MI, pathological remodelling causes the ventricle to enlarge, become spherical in shape, and functionally deteriorate

Author biographies

Thomas J. Cahill is a Cardiology Specialist Registrar and Wellcome Trust Doctoral Fellow based at the University of Oxford and Oxford Heart Centre, John Radcliffe Hospital. He read Natural Sciences at the University of Cambridge before studying clinical medicine at University College London. His doctoral research focuses on mechanisms of cardiac regeneration and repair, specifically the roles of macrophages and inflammation.

Robin P. Choudhury is Professor of Cardiovascular Medicine at the University of Oxford, where he is director of the Acute Vascular Imaging Centre and an interventional cardiologist. His training was in Oxford, London, and New York. He is a Fellow of Balliol College and of the Royal College of Physicians. His interests are in the characterization of patients with atherosclerosis and vascular inflammation and in particular in the development, validation, and application of new approaches to vascular imaging. He is the principal investigator of the Tripartite Immunometabolism Consortium.

Paul R. Riley took up the Chair of Development and Cell Biology in the Department of Physiology, Anatomy and Genetics in 2011, having been awarded a British Heart Foundation Personal Chair of Regenerative Medicine. He is also director of the virtual BHF Oxbridge Centre for Regenerative Medicine. He was formerly Professor of Molecular Cardiology at the UCL Institute of Child Health, London, where he was a principal investigator within the Molecular Medicine Unit for 12 years. His research interests are in cardiovascular development and regeneration.

Key points

Endogenous regeneration seen in animal models provides a template for optimal repair of the human heart following MI.

In the regenerating heart new cardiomyocytes are produced by proliferation of the existing cardiomyocyte pool. Understanding and targeting the intrinsic mechanisms which regulate cardiomyocyte cell cycle re-entry could enable therapeutic regeneration in the human heart.

Repair is modulated by epicardial activation, neoangiogenesis, the immune response and the extracellular matrix. Biological insights from regenerative models, combined with use of high-throughput phenotypic screens and *in vivo* discovery approaches, are uncovering novel therapeutic targets and compounds to improve repair.

Regenerative strategies emerging from increased understanding of cardiomyocyte lineage specification include transplantation of *in vitro*-produced cardiomyocytes and *in vivo* reprogramming of fibroblasts. Current efforts to improve engraftment, maturation, and targeting will enable a next generation of trials.

Distinct approaches are required for patients in the immediate post-MI period and for those with chronic HF, and high risk strategies should be targeted at the latter group. Clinical trial design should be tailored to incorporate informed biological endpoints alongside functional endpoints.

TOC

Regeneration of the heart by cardiomyocyte reconstitution represents an attractive approach to treat heart failure. Here, Riley and colleagues discuss recent insights into the biology of heart regeneration and highlight emerging therapeutic regenerative strategies for HF. Challenges and considerations in the translation of regenerative therapies into the clinic are discussed. [\[Au:OK?\]](#)

Subject categories

Biological sciences / Drug discovery [\[URI /631/154\]](#)

Biological sciences / Physiology / Cardiovascular biology / Cardiovascular diseases [\[URI /631/443/592/75\]](#)

Biological sciences / Biotechnology / Regenerative medicine [\[URI /631/61/490\]](#)

